United States Securities and Exchange Commission

Washington, D.C. 20549

Form 10-K

☒ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934:

For the fiscal year ending August 31, ~~2017~~2018

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934: For the transition period from ___________ to ___________.

Commission file number: 333-154989

ENTEST ~~BIOMEDICAL~~GROUP, INC.

(Name of small business issuer in its charter)

Nevada		26-3431263
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

4700 Spring Street, Suite 304, La Mesa, California, 91942

(Address of Principal executive offices)

Issuer’s telephone number: ( 619) 702-1404

_______________

Securities registered under Section 12(b) of the “Exchange Act” None

Securities registered under Section 12(g) of the Exchange Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or smaller reporting company.

Large accelerated filer ☐	Accelerated filer ☐
Non accelerated filer ☐	Smaller reporting Company ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ ☒ No ☒☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No☐

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, as of the last business day of the registrant’s most recently completed second fiscal quarter: $~~592~~ 470,~~153~~842

As of November 2216, ~~2017~~2018 Entest BioMedical, Inc. had 49,~~171~~170,~~072~~472 common shares outstanding, 728, 009 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding , ~~533~~534 Series AAA preferred shares outstanding and 1001533 shares outstanding of the Company’s Non Voting Convertible Preferred Stock. .

In this annual report, the terms “Entest BioMedical, Inc.. ”, “Entest”, “Company”, “we”, or “our”, unless the context otherwise requires, mean Entest BioMedical, Inc., a Nevada corporation, and its subsidiaries.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This annual report on Form 10-K and other reports that we file with the SEC contain statements that are considered forward-looking statements. Forward-looking statements give the Company’s current expectations, plans, objectives, assumptions or forecasts of future events. All statements other than statements of current or historical fact contained in this annual report, including statements regarding the Company’s future financial position, business strategy, budgets, projected costs and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “plans,” “potential,” “projects,” “ongoing,” “expects,” “management believes,” “we believe,” “we intend,” and similar expressions. These statements are based on the Company’s current plans and are subject to risks and uncertainties, and as such the Company’s actual future activities and results of operations may be materially different from those set forth in the forward looking statements. Any or all of the forward-looking statements in this annual report may turn out to be inaccurate and as such, you should not place undue reliance on these forward-looking statements. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. The forward-looking statements can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and assumptions due to a number of factors~~, including:~~.

• dependence on key personnel; • competitive factors; • degree of success of research and development programs • the operation of our business; and • general economic conditions

These forward-looking statements speak only as of the date on which they are made, and except to the extent required by federal securities laws, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the cautionary statements contained in this annual report.

PART I

Item 1. Business

We were incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. Until July 10, 2009, our principal business objective was the offering of active/leisure fashion design clothing.

On July 10, 2009 we abandoned our efforts in the field of active/leisure fashion design clothing when we acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”) from Bio-Matrix Scientific Group, Inc. (“BMSN”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by Mr. Rick Plote.

As a result of this transaction, the former stockholder of Entest CA held approximately 70% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by Entest CA under the purchase method of accounting, and was treated as a recapitalization with Entest CA as the acquirer..

Upon acquisition of Entest CA, we abandoned our efforts in the field of active/leisure fashion design clothing. On July 12, 2009 we adopted the name of Entest CA when we changed our name to Entest BioMedical, Inc. On June 18, 2015 Entest established Zander Therapeutics, Inc., ~~currently~~ a ~~majority~~then wholly owned subsidiary.. WeZander ~~intend~~was established to engage primarily in the development and commercialization of veterinary medical therapies which we intend to license from other entities as well as develop internally

OnThe ~~June~~Company ~~23,~~changed ~~2015~~its ~~Regen~~name ~~Biopharma,~~to ~~Inc.~~Entest ~~(“Regen”) entered into an agreement (“Agreement”) with Zander Therapeutics~~Group, Inc. (“Zander”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years. The Agreement was amended on ~~September~~February 12, 2017 to grant an exclusive worldwide right and license for the development and commercialization of all intellectual property controlled by Regen exclusive of trademarks (“License IP”) for non-human veterinary therapeutic use2018.

~~Pursuant~~On toMay ~~the Agreement~~5, ~~Zander shall pay to Regen a one-time~~2018, ~~non-refundable,~~The ~~upfront~~Company ~~payment~~declared ofthe ~~one~~distribution ~~hundred~~on ~~thousand~~a USpro ~~dollars~~rata ~~($100,000)~~ basis as a ~~license~~dividend ~~initiation~~in ~~fee~~kind ~~which must be paid within 90 days~~ of ~~June 23~~3,000,000 ~~2015~~of ~~and~~the ancommon ~~annual non-refundable payment~~ shares of ~~one~~Zander ~~hundred thousand~~Therapeutics, ~~US dollars ($100~~Inc.,~~000)~~ onpar ~~July~~value ~~15th~~$0.0001, ~~2016~~currently ~~and~~owned ~~each~~by ~~subsequent~~Entest ~~anniversary~~Group, ~~of the effective date of the Agreement~~Inc. to:

~~The~~(a) ~~abovementioned~~Holders ~~payments~~of ~~may~~record beof ~~made,~~the atoutstanding ~~Zander’s discretion, in cash or newly issued~~ common ~~stock~~shares of ~~Zander~~the orCompany ~~in common stock of Entest BioMedical Inc. valued~~ as of the ~~lowest~~record ~~closing~~date, ~~price on the principal exchange upon~~ which ~~said~~is ~~common~~May ~~stock~~30, ~~trades publicly within the 14 trading days prior to issuance~~2018.

~~Pursuant~~(b) toHolders ~~the~~of ~~Agreement,~~record ~~Zander~~of ~~shall~~the ~~pay~~shares toof ~~Regen~~any ~~royalties~~outstanding ~~equal~~series toof ~~four~~the ~~percent~~preferred ~~(4%)~~shares of the ~~Net~~Company ~~Sales,~~ as ~~such~~of ~~term is defined in~~ the ~~Agreement,~~record ~~of any Licensed Products~~date, ~~as such term~~ which is ~~defined~~May ~~in the Agreement~~30, ~~in a Quarter~~2018.

~~Pursuant~~Shareholders toof the ~~Agreement,~~Company ~~Zander~~shall ~~will~~receive ~~pay~~one ~~Regen ten percent~~ (~~10%~~1) ofcommon ~~all~~share ~~consideration (in the case~~ of ~~in-kind~~Zander ~~consideration~~Therapeutics, atInc. ~~fair market~~for ~~value~~each as17 ~~monetary~~common ~~consideration)~~and/or ~~received~~preferred byshares ~~Zander~~of ~~from~~the Company ~~sublicensees~~held ~~(excluding~~as ~~royalties~~of ~~from~~the ~~sublicensees~~record ~~based~~date. onThe ~~Net Sales~~distribution of ~~any~~the ~~Licensed~~3,000,000 ~~Products~~common ~~for~~shares ~~which~~of ~~Regen~~Zander ~~receives~~Therapeutics, ~~payment~~Inc. ~~pursuant~~ to the ~~terms~~ common and ~~conditions~~preferred shareholders of the ~~Agreement~~Company occurred on June 11, 2018 ("Distribution Date").

~~Zander~~As isa ~~obligated~~result ~~pay~~of tothe ~~Regen~~payment ~~minimum~~of ~~annual~~the ~~royalties~~abovementioned property dividend, the Company’s percentage of ~~ten~~ownership ~~thousand~~of USZander ~~dollars~~fell ~~($10,000)~~below 50% ~~payable~~resulting ~~per~~in ~~year~~the ondeconsolidation ~~each~~of ~~anniversary~~Zander as of the ~~Effective~~Distribution Date. As of ~~this~~the ~~Agreement,~~Distribution ~~commencing~~Date onall assets and liabilities attributable to Zander were derecognized by the ~~second~~Company. ~~anniversary~~The ofCompany ~~June~~recognized 23a $10,034 ~~2015.~~gain ~~This~~as ~~minimum~~a ~~annual~~result ~~royalty~~of isthe ~~only~~deconsolidation. ~~payable~~The Property dividend may be deemed to ~~the~~have ~~extent~~occurred ~~that~~with ~~royalty~~a ~~payments~~related ~~made~~party ~~during~~as the ~~preceding~~recipients ~~12-month~~were ~~period~~shareholders doof ~~not~~Entest, ~~exceed~~including the ~~ten~~Chairman ~~thousand~~and USChief ~~dollars~~Executive ~~($10~~Officer of Entest and Regen Biopharma,~~000)~~ Inc. which is a company under common control with Entest.

The ~~Agreement~~Company’s ~~may~~remaining beshare ~~terminated~~of Zander , which consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) is accounted for under the Equity Method as of the Distribution Date. The Zander M Stock is carried a Fair Value and the carrying value is increased by ~~Regen:~~the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value . As of August 31, 2018 the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.

IfAs ~~Zander has not sold any Licensed Product by ten years~~ of ~~the~~November ~~effective~~16, ~~date~~2018 of the ~~Agreement~~Company oris ~~Zander~~a ~~has~~“shell ~~not~~company” ~~sold~~as ~~any~~that ~~Licensed Product~~term ~~for~~is ~~any~~defined ~~twelve~~in ~~(12)~~Rule ~~month~~12b-2 ~~period~~of ~~after~~the ~~Zander’s~~Securities ~~first~~and Exchange ~~commercial~~Act ~~sale~~which ofis a ~~Licensed~~registrant ~~Product.~~that has:

~~The~~(1) ~~Agreement~~No ~~may~~or benominal ~~terminated~~operations; ~~by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent~~ and ~~Trademark Office to Regen with regard to that License IP.~~

~~The~~(2) Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to Regen with regard to that License IP is terminated.Either:

~~The~~(i) ~~Agreement~~No ~~may~~or benominal ~~terminated by either party in the event of a material breach by the other party.~~assets;

~~The~~(ii) ~~Chairman~~Assets ~~and~~consisting ~~Chief~~solely ~~Executive Officer~~ of ~~Regen~~cash ~~is David R. Koos who also serves as the Chairman~~ and ~~Chief~~cash ~~Executive~~equivalents; ~~Officer of the Company and Zander.~~or

~~The~~(iii) ~~President~~Assets consisting of ~~Regen~~any isamount ~~Harry~~of ~~Lander~~cash ~~who~~and ~~also~~cash ~~serves~~equivalents asand ~~President~~nominal ofother ~~Zander~~assets.

The ~~Chief~~Company's ~~Financial~~current ~~Officer~~business ofstrategy ~~Regen~~ is ~~Todd~~to ~~Caven~~acquire ~~who~~an ~~also~~operating ~~serves~~company asseeking ~~Chief~~the ~~Financial~~perceived ~~Officer~~advantages of ~~Zander~~being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders.

On September 28, 2015 Entest issued 8,000,000 of its common shares to Regen on behalf Zander in satisfaction of the license initiation fee.

During the quarter ended November 30, 2016 Entest paid $17,000 to Regen on behalf of Zander as a partial payment of the July 15th, 2016 liability.

On May 30, 2017 the Entest issued 83,000 shares of its Non Voting Convertible Preferred Stock on behalf of Zander to Regen in satisfaction of $83,000 of the July 15th, 2016 liability.

On July 24th, 2017 Entest issued 102,852 shares of its Non Voting Convertible Preferred Stock on behalf of Zander to Regen in satisfaction of a $100,000 anniversary fee and $2,852 of minimum royalties payable by Zander Therapeutics pursuant to the Agreement.

As of November 22, 2017, we have not licensed, developed or commercialized any existing veterinary medical therapies. Intellectual properties licensed to Zander by Regen Biopharma, Inc., a company under common control with us, comprise the therapeutic concept behind ZAN-100 and ZAN-200, two therapies in early stage development by Zander.

NR2F6

Both of Zander’s products under development will operate through either inhibition or activation by small (low molecular weight) molecules of the nuclear receptor NR2F6. Nuclear receptors are a class of proteins found within cells that are responsible for sensing certain other molecules. In response, these receptors work with other proteins to regulate the expression of specific genes.

ZAN-100

ZAN-100 is intended to be a veterinary cancer therapy. In the opinion of Zander, the studies performed by Hermann-Kleiter et al. (The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Reports 12, 2072–2085 (2015)) demonstrate that the inhibition of NR2F6 in T cells may yield anti-cancer benefits in small animals. The studies indicate that, in the presence of NR2F6, T cell activation is limited within the tumor microenvironment. Zander believes that inhibition of NR2F6 removes a barrier to the animal’s own immune system’s ability to attack cancer cells. ZAN-100 is intended to be a small molecule therapy whose mode of action will be the inhibition of NR2F6.

High throughput screening assays conducted for Regen Biopharma, Inc. (the licensor of the intellectual property which forms the basis for Zander’s products in development) between July and September of 2016 on thirty thousand compounds yielded four newly discovered small molecule compounds which (a) can bind to the relevant structure in a cellular system and (b) show evidence of the ability to modulate the effects of NR2F6.

ZAN-200

ZAN-200 is intended to be a veterinary arthritis therapy. Rheumatoid arthritis is an immune-mediated disease. This means it is caused by an overreaction of the immune system. In rheumatoid arthritis, the body mistakes some of its own protein for foreign protein. It then makes antibodies against its own protein. In the opinion of Zander, suppression of the immune system through activation of NR2F6 in those immune cells would be an effective therapy. ZAN-200 is intended to operate by activating NR2F6 in the animals’ immune cells.

Ex-vivo assays were performed using immune cells from five dog blood samples. Data derived from those tests demonstrated the ZAN-200 may inhibit T cell activation and production of cytokines, particularly IL-17 and IL-2. IL-17 and IL-2 have been shown to create inflammatory responses leading to arthritic conditions.

We have filed applications with the United States Patent and Trademark Office for patent protection with respect to internally developed intellectual property covering our products in development. As of November 22, 2017 no patent protection has been granted to any intellectual property developed by Zander.

Neither of the Company or Zander has undertaken any discussions with any pharmaceutical companies regarding the commercialization of any products under development. None of Zander or the Company’s products have been approved by any regulatory body for marketing within the United States or anywhere else. No assurance can be given that all or any of Zander or the Company’s currently planned products will ever be commercialized.

Principal Products and Services

NR2F6

ZAN-100

Zander has begun development of the ZAN-100 veterinary drug line. ZAN-100 is intended to be a veterinary cancer therapy. In the opinion of Zander, the studies performed by Hermann-Kleiter et al. (The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Reports 12, 2072–2085 (2015)) demonstrate that the inhibition of NR2F6 in T cells may yield anti-cancer benefits in small animals. The studies indicate that, in the presence of NR2F6, T cell activation is limited within the tumor microenvironment. Zander believes that inhibition of NR2F6 removes a barrier to the animal’s own immune system’s ability to attack cancer cells. ZAN-100 is intended to be a small molecule therapy whose mode of action will be the inhibition of NR2F6.

ZAN-200

Zander has begun development of the ZAN-200 veterinary drug line. ZAN-200 is intended to be a veterinary arthritis therapy. Rheumatoid arthritis is an immune-mediated disease. This means it is caused by an overreaction of the immune system. In rheumatoid arthritis, the body mistakes some of its own protein for foreign protein. It then makes antibodies against its own protein. In the opinion of Zander, suppression of the immune system through activation of NR2F6 in those immune cells would be an effective therapy. ZAN-200 is intended to operate by activating NR2F6 in the animals’ immune cells.

Development Conducted to Date

High Throughput Screening Assay

Initial high throughput screening assays were performed in July to September of 2016 by the contract research organization Proteros, GMBH for Regen Biopharma, Inc. This assay is based on Regen Biopharma Inc.’s screening assay whereby the full-length or ligand-binding domain of NR2F6 Reporter gene assays are used to screen for compounds that modulate gene expression via binding to nuclear hormone receptors. Transfer of this assay to ChemDiv, Inc., another contract research organization, by Regen Biopharma, Inc. was effected in January, 2017.

In molecular biology, a reporter gene is a gene that researchers attach to a regulatory sequence of another gene of interest in bacteria, cell culture, animals or plants. Certain genes are chosen as reporters because the characteristics they confer on organisms expressing them are easily identified and measured, or because they are selectable markers. Reporter genes are often used as an indication of whether a certain gene has been taken up by or expressed in the cell or organism population.

High Throughput Screens (HTS) are recent scientific methods in which hundreds of thousands of experimental samples are subjected to simultaneous testing under given conditions. Through this process one can rapidly identify active compounds, antibodies, or genes that modulate a particular biomolecular pathway. The results of these experiments provide starting points for drug design and for understanding the interaction or role of a particular biochemical process in biology.

HTS performed on behalf of Regen Biopharma, Inc. have been ongoing as of September 9, 2016. As of September 9, 2016 four newly discovered small molecule compounds which (a) can bind to the relevant structure in a cellular system and (b) show evidence of the ability to modulate activity of NR2F6 have been discovered.

Results of any studies conducted by Regen Biopharma, Inc. are being made available to Zander Theraputics, Inc.for use in veterinary drug development and commercialization.

Ex Vivo Assay

Ex-vivo assays were performed using immune cells from canine blood samples from five dogs. The samples were treated with compound at various concentrations and the supernatant assayed for the presence of various cytokines using ELISA-based assays. Enzyme-linked immunosorbent assay (ELISA is a biochemical technique used mainly in immunology to detect the presence of an antibody or an antigen in a sample). These assays were commenced in May, 2017 and are ongoing as of September 9, 2017.

Data derived from the five dog study indicated that the ZAN-200 series drugs could inhibit T cell activation and production of cytokines, particularly IL-17 and IL-2. IL-17 and IL-2 have been shown to create inflammatory responses leading to arthritic conditions.

Distribution methods of the products or services:

ItEntest iscurrently ~~anticipated~~provides ~~that~~no ~~Zander~~product ~~will enter into licensing and/~~or ~~sublicensing agreements with outside entities in order that Zander may obtain royalty income on the products and services which it may develop and commercialize.~~service

~~Competitive business conditions and Zander's competitive position in the industry and methods of competition~~3

WeCompetitive ~~have~~business ~~yet~~conditions toand ~~achieve~~Entest's ~~revenues~~competitive orposition ~~profits.~~in ~~The~~the ~~veterinary pharmaceutical~~ industry ~~in which we intend to compete are highly competitive~~ and ~~characterized~~methods ~~by rapid technological advancement. Many~~ of ~~our competitors have greater resources than we do.~~ competition

WeThe ~~intend~~Company will face vast competition from other shell companies that desire to seek a potential business combination with a private company seeking the perceived advantages of being a publicly held corporation. The Company will be in a highly competitive bymarket for ~~utilizing~~a small number of business opportunities which could reduce the ~~services~~likelihood ~~and~~of ~~advice~~consummating a successful business combination. A large number of ~~individuals~~established ~~that~~and wewell-financed ~~believe~~entities, ~~have~~including ~~expertise~~small inpublic ~~their~~companies ~~field~~and inventure capital firms, are active ~~order~~in mergers and acquisitions of companies that wemay ~~can~~be ~~concentrate~~desirable ~~our~~target ~~resources~~candidates onfor ~~projects in~~us. ~~which~~Nearly ~~products~~all these entities have significantly greater financial resources, technical expertise and ~~services~~managerial incapabilities ~~which~~than we ~~have~~do; ~~the~~consequently, ~~greatest~~we ~~potential~~will be at a competitive todisadvantage ~~secure~~in identifying possible business opportunities and successfully completing a business combination. These competitive factors ~~advantage~~ may bereduce ~~developed~~the likelihood of our identifying and ~~commercialized~~consummating .a successful business

To that effect, Zander has entered into nonemployee consulting agreements with individuals who we believe have a high level of expertise in their professional fields and who have agreed to provide counsel and assistance to Zander in (a) determining the viability of proposed projects (b) obtaining financing for projects and (c) obtaining the resources required to initiate and complete a project in the most cost effective and rapid mannercombination.

These individuals are as follows:

Brian Devine

Mr. Brian Devine has agreed to act as Chairman of Zander’s Business Advisory Board.

Mr. Devine has served as Chairman Emeritus of Petco Holdings, Inc. from March 2016 to October 2016, Chairman of the Board of Directors of Petco Animal Supplies Stores, Inc. from 1994 until March 2016 and as President and Chief Executive Officer of PETCO Animal Supplies, Inc. from 1990 until 2004.

On June 21, 2017 Zander entered into an agreement (“Agreement”) with Mr. Brian Devine whereby Mr. Devine shall serve as Chairman of Zander’s Business Advisory Board.

The term of the Agreement shall commence on June 23, 2017 and shall expire on June 23, 2020. The term of the Agreement may be extended by mutual agreement.

Pursuant to the Agreement:

(a) Mr. Devine shall, for so long as he remains a member of the Business Advisory Board, meet with Zander upon written request, at dates and times mutually agreeable to Candidate and Zander, to discuss any matter involving Zander or its Subsidiaries

(b) Identify and introduce to Zander persons to serve as members of Zander's Business Advisory Board ("Advisory Candidates").

Pursuant to the Agreement:

(i) Mr. Devine received 500,000 of the common shares of Zander.

(ii) In the event that an Advisory Candidate identified and introduced by Mr. Devine to Zander serves as a member of the Business Advisory Board of Zander, Mr. Devine shall receive, ten business days subsequent to the completion of 12 months service by the Advisory Candidate as a member of the Business Advisory Board of Zander, a fee paid in the common shares of Zander, equal to 5% of any shares of Zander issued to the Advisory Candidate.

Dr. Thomas Donnelly, DVM

Dr. Thomas Donnelly has agreed to act as a Senior Veterinary Advisor to Zander. Dr. Donnelly is a board-certified specialist in the field of laboratory animal medicine, an Adjunct Associate Professor at Tufts University Cummings School of Veterinary Medicine and a Professor at Ecole Nationale Veterinaire d’Alfort, a French public institution of scientific research and higher education in veterinary medicine.

On August 7, 2017 Zander entered into an agreement (“Agreement”) with Dr. Donnelly whereby Dr. Donnelly shall serve as Senior Veterinary Advisor to Zander. The term of the Agreement shall be from August 17, 2017 and shall expire on August 16, 2018. The term of this Agreement may be extended by mutual consent.

Pursuant to the Agreement:

(a) Dr. Donnelly shall advise Zander on various nominal matters regarding veterinary ''Nominal" is defined as periodic conversations in which Dr. Donnelly is asked for a referral to an appropriate researcher on a specific topic or input on research data Zander is developing.

(b) In the event Dr. Donnelly is requested to provide research services, such services will be negotiated separately between Dr. Donnelly and Zander.

As consideration for his services pursuant to this Agreement, Dr. Donnelly received 500,000 of Zander’s Series M Preferred Shares on August 21, 2017.

Dr. Donnelly is also party to another agreement between the Company and Dr. Donnelly (“ENTB Agreement”) whereby Dr. Donnelly shall provide similar services to Zander as those to be provided under the Agreement.

Consideration pursuant to the ENTB Agreement was 100,000 shares of the Series B Preferred Stock of ENTB (“Compensation Shares”).Within 30 business days subsequent to the effective date of a Registration Statement filed under the Securities Act of 1933, as amended, registering common shares of Zander (“Zander Registration Statement”) Donnelly shall have the right to exchange up to the total number of the Compensation Shares issued pursuant to the terms and conditions of the ENTB Agreement for an equivalent number of the common shares of Zander Therapeutic, Inc. six months subsequent to the date that the Zander Registration Statement is declared effective by the United States Securities and Exchange Commission. The term of the ENTB Agreement is March 1, 2017 to February 29, 2019.

Dr. Thomas Ichim, PhD Senior Research Consultant

Dr. Thomas Ichim has agreed to act as Senior Research Consultant to Zander. Dr. Ichim has served as a director and as President of Creative Medical Technology, Inc. since February 2016, and has served Chief Scientific Officer of Creative Medical Technology Holdings, Inc. since March 2017. Between 2007 and 2015 Dr. Ichim served as Chief Science Officer, Chief Executive Officer, President, and member of the Board of Directors of MediStem Inc., a San Diego-based company engaged in development of endometrial regenerative cells which was acquired in 2014 by Intrexon Corporation. From 2004 until 2007 he served as program manager for biorasi LLC, a clinical research organization. Between October 2012 and September 2015 Dr. Ichim served as Chief Scientific Officer and Director of research at Regen Biopharma, Inc., a company under common control with Zander. Thomas Ichim serves at will and is not party to a consulting contract with Zander

Debbie Dorsee Director of Business Development

Ms. Debbie Dorsee has agreed to act as Director of Business Development for Zander. Ms. Dorsee is the founder and principal officer of the Dorsee Company, a San Diego based public relations firm. Debbie Dorsee serves at will and is not party to a consulting contract with Zander.

Dr. Linda L. Black, DVM, PhD

Dr. Linda L. Black has agreed to act as a Senior Veterinary Advisor to Zander.

On March 20, 2017 the Company entered into an agreement (“Agreement”) with Dr. Black whereby Dr. Black shall serve as Senior Veterinary Advisor to Zander. The term of the Agreement shall be from March 20 2017 and shall expire on March 19, 2018. The term of this Agreement may be extended by mutual consent.

Pursuant to the Agreement:

(a) Dr. Black shall advise Zander on various nominal matters regarding veterinary ''Nominal" is defined as periodic conversations in which Dr. Donnelly is asked for a referral to an appropriate researcher on a specific topic or input on research data Zander is developing.

(b) In the event Dr. Black is requested to provide research services, such services will be negotiated separately between Dr. Black and Zander.

(c) As consideration of the performance of services pursuant to this Agreement, Black shall receive 100,000 shares of the Series B Preferred Stock of the Company (“Compensation Shares”).Within 30 business days subsequent to the effective date of a Registration Statement filed under the Securities Act of 1933, as amended, registering common shares of Zander (“Zander Registration Statement”) Black shall have the right to exchange up to the total number of the Compensation Shares issued pursuant to the terms and conditions of this Agreement for an equivalent number of the common shares of Zander Therapeutic, Inc. six months subsequent to the date that the Zander Registration Statement is declared effective by the United States Securities and Exchange Commission.

Dr. Black currently serves as Chief Operating Officer and Vice President of Clinical Science for Medicus Biosciences, a biotech company focused on drug delivery for ophthalmology, advanced wound healing, osteoarthritis, and regenerative medicine applications both veterinary and non-veterinary.

On June 20th, 2017 Zander issued 500,000 of Zander’s Series M Preferred shares as consideration for services provided by Dr. Black to Zander.

Jonathan Baell, Ph.D.

On August 16th 2017 Professor Jonathan Baell entered into an agreement (“Agreement”) with Zander whereby, pursuant to the Agreement:

(a) Baell shall advise Zander on various nominal matters regarding veterinary. ''Nominal" is defined as periodic conversations in which Baell is asked for a referral to an appropriate researcher on a specific topic or input on research data Zander is developing.

(b) In the event Baell is requested to provide research services, such services will be negotiated separately between Baell and Zander.

The term of the Agreement is from August 17, 2017 to August 18, 2018. Baell was issued 400,000 of Zander’s Series M Preferred stock pursuant to the terms of the Agreement. 100,000 of Zander’s Series M Preferred stock was issued to Baell prior to entering into the Agreement.

Prof. Jonathan Baell, Ph.D. is a Larkins Fellow, Co-Director of the Australian Translational Medicinal Chemistry Facility and an National Health and Medical Research Council Senior Research Fellow at Monash Institute of Pharmaceutical Sciences (MIPS) located in Australia.

Robin Gasser Ph.D., BVM, DVM, DVSc

On August 7th 2017 Professor Robin Gasser entered into an agreement (“Agreement”) with Zander whereby, pursuant to the Agreement:

(a) Gasser shall advise Zander on various nominal matters regarding veterinary ''Nominal" is defined as periodic conversations in which Gasser is asked for a referral to an appropriate researcher on a specific topic or input on research data Zander is developing.

(b) In the event Gasser is requested to provide research services, such services will be negotiated separately between Gasser and Zander.

The term of the Agreement is from August 17, 2017 to August 16, 2018. Gasser was issued 500,000 of Zander’s Series M Preferred stock pursuant to the terms of the Agreement.

Prof. Gasser is a Professor at the University of Melbourne Faculty of Veterinary Science and serves as President of the Australian Society for Parasitology

Sources and availability of raw materials and the names of principal suppliers

The supplies and materials required to conduct our operations are available through a wide variety of sources and may be obtained through a wide variety of sources.

Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including duration

Other than that license granted by Regen to Zander whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years, Zander and/or the Company has not been granted any license to develop and commercialize any third party intellectual property.

Company has been granted no patents. Certain intellectual property licensed to Zander by Regen has been granted patent protection (“Patented IP”). The Patented IP is as follows:

Title	Inventors	Country	Number
GENETIC CONSTRUCTS FOR DELAYING OR REPRESSING THE EXPRESSION OF A TARGET GENE (‘099”)	Graham, Rice, Waterhouse	US	6,573,099
SYNTHETIC GENES AND GENETIC CONSTRUCTS COMPRISING THE SAME (Graham Family)	Waterhouse, Graham, Wang, Rice	US	8,067,383 (was 10/346,853)
		US	11/218,999
		US	7754697
		US	8048670 (was 10/759,841)
		US	8053419 (was 10/821,726)
		US	90/007,247
CONTROL OF GENE EXPRESSION WO99/49029	Graham, Rice, Waterhouse, Wang	AU	743316
		AU	2005211538
		AU	2005209648
		AU	2008249157
		BR	PI9908967.0
		BR	PI9917642.4
		CA	2323726
		CN	200510083325.1
		CN	200910206175
		CZ	295108
		EP	1555317 (formerly patent application no. 04015041.9)
		EP	1624060 (formerly patent application no.05013010.3
		EP	07008204.5
		EP	10183258.2
		UK	GB 2353282
		HK	1035742
		HG	PO5000631
		HG	PO101225
		IN	3901/DELNP/2005
		IN	2000/00169/DE
		JP	2000-537990
		JP	2005-223953
		JP	2007-302237
		JP	2009-161847
		KR	10-2010-7006892 Divisional of 7010419/00
		MX	PA/a/2000/008631
		MX	PA/a/2005/006838
		NZ	506648
		NZ	547283
		PL	P-377017
		SG	75542
		SG	200205122.5
		SG	141233
		SL	287538
		ZA	2000/4507
		SG	141233
Patent Name	Inventors	Country	Application/ Grant No
METHODS AND MEANS FOR OBTAINING MODIFIED PHENOTYPES	Waterhouse, Wang, Graham	AU	29514/99 (760041)
		AU	2007201023
		CA	2325344
		CN	ZL99805925.0 (CN1202246-C)
		EP	99910592.7 (EP1068311)
		JP	2000-543598
		NZ	507093
		US	09/287632
		US	11/364183
		US	11/841737 US20080104732.

Title	Inventors	Country	Number
GENETIC SILENCING	Graham, Rice, Murphy, Reed	JP	2001-569332
		BR	PI0109269-3
		UK	GB2377221
		SG	91678
		ZA	2002/07428
DOUBLE-STRANDED NUCLEIC ACID (LONG HAIR PIN)	Graham, Rice, Roelvink, Suhy, Kolkykhalov, Harrison, Reed.	AU	2004243347
		NZ	543815
		EP	04735856.9
		CA	2527907
		JP	2006-508084
		ZA	2005/09813
		SG	200507474-5
		IL	172191
		US	12/914893 Continuation of 10/861191
RNAi EXPRESSION CONSTRUCTS (single promoter)	Roelvink, Suhy, Kolykhalov, Couto	US	7,803,611
		US	11/883645
		CN	200680010811.3
		HK	08112495.7
		EP	09015950.0
		CA	2596711
		AU	2006210443
		IL	185315
		NZ	560936

US Patent #8389708

METHOD OF CANCER TREATMENT USING SIRNA SILENCING

The present invention is a method for the treatment of cancer involving tumor derived immunosuppression in a subject. The method comprises administering to a subject one or more siRNA constructs capable of inhibiting the expression of an immunosuppressive molecule. The invention also provides siRNA constructs and compositions.

US Patent #9091696 MODULATION OF NR2F6 AND METHODS AND USES THEREOF

The application provides methods of modulating NR2F6 in a cell or animal in need thereof by administering an effective amount of a NR2F6 modulator.

US Patent #8263571

GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS)

The Company and/or Zander has no trademarks.

The Company and/or Zander is not party to any binding labor contracts.

Need for any government approval of principal products or services, effect of existing or probable governmental regulations on the business

The ~~Center~~Company ~~for~~is ~~Veterinary~~unaware ~~Medicine~~of ~~(“CVM”)~~any atgovernment ~~the~~approval ~~United~~currently ~~States~~required ~~Food~~in ~~and~~order ~~Drug~~for ~~Administration (“FDA”) regulates animal pharmaceuticals under~~ the ~~Food,~~Company ~~Drug~~to ~~and~~complete ~~Cosmetics~~an ~~Act.~~acquisition ~~Our current proposed products are animal pharmaceuticals regulated by the CVM. Manufacturers~~ of ~~animal~~an ~~health pharmaceuticals must show their products to be safe, effective and produced by a consistent~~operating ~~method of manufacture~~company. The ~~CVM’s~~Company ~~basis for approving a drug application~~ is ~~documented~~subject ~~in a Freedom of Information Summary. We will be required~~ to ~~conduct~~federal ~~post-approval monitoring of FDA approved pharmaceutical products~~ and tostate ~~submit~~securities ~~reports of product quality defects, adverse events or unexpected results to the CVM’s Surveillance and Compliance group~~laws. Each other country outside the United States of America has its own regulatory requirements for approving and marketing veterinary pharmaceuticals which the Company must comply with prior to marketing animal drugs in those countries.

Amount spent during the last fiscal year on research and development activities

During the fiscal year ended August 31, ~~2017~~2018 wethe consolidated Company expended $~~124~~949,~~770~~584 on research and development activities.

Costs and effects of compliance with environmental laws (federal, state and local);

Entest has not incurred any unusual or significant costs to remain in compliance with any environmental laws and does not expect to incur any unusual or significant costs to remain in compliance with any environmental laws in the foreseeable future.

Number of total employees and number of full-time employees

As of November 2216, ~~2017~~2018, the ~~consolidated~~ Company has 31 employee of which 1 is ~~full~~partl time.

13Sources and availability of raw materials and the names of principal suppliers

Entest currently has no need for raw materials or supplies

Patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, including duration.

Entest possesses no patents or trademarks. Entest has not been granted any license, franchise or concession. Entest is not party to any royalty agreement or labor contract.

Item 2. Properties

On November 1, 2011, the Company entered into an agreement to lease approximately 2,320 square feet of office space beginning December 1, 2011 for a period of five years.

Rent to be charged to the Company pursuant to the lease is as follows:

$2,996 per month for the period beginning December 1, 2011 and ending November 30, 2012

$3,116 per month for the period beginning December 1, 2012 and ending November 30, 2013

$3,241 per month for the period beginning December 1, 2013 and ending November 30, 2014

$3,371 per month for the period beginning December 1, 2014 and ending November 30, 2015

$3,506 per month for the period beginning December 1, 2015 and ending November 30, 2016

On November 27, 2016 the lease was extended until November 30, 2021

Rent to be charged to the Company pursuant to the extension is as follows:

$2,996 per month for the period beginning December 1, 2016 and ending November 30, 2017

$3,116 per month for the period beginning December 1, 2017 and ending November 30, 2018

$3,241 per month for the period beginning December 1, 2018 and ending November 30, 2019

$3,371 per month for the period beginning December 1, 2019 and ending November 30, 2020

$3,506 per month for the period beginning December 1, 2020 and ending November 30, 2021

This property is utilized as office space. The Company believes that the foregoing property is adequate to meet its current needs. ~~While it is anticipated that the Company will require access to laboratory facilities in the future, the Company believes that access to such facilities are available from a variety of sources.~~

Item 3. Legal Proceedings

None

Item 4. Submission of Matters to a Vote of Security Holders

No matter was submitted during the fourth quarter of the fiscal year covered by this report to a vote of security holders, through the solicitation of proxies or otherwise.

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

The Company’s common stock is a "penny stock," as defined in Rule 3a51-1 under the Exchange Act. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its sales person in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. In addition, the penny stock rules require that the broker-dealer, not otherwise exempt from such rules, must make a special written determination that the penny stock is suitable for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure rules have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules. So long as the common stock of the Company is subject to the penny stock rules, it may be more difficult to sell common stock of the Company.

14The Company’s authorized capital stock consists of 500,000,000 shares of common stock with a par value $0.0001, and 5,000,000 shares of preferred stock with a par value $0.0001 per share (of which 100,000 are designated as Series AA Preferred Stock, 4,400,000 are designated as Series B Preferred Stock and 300,000 are designated as Series AAA Preferred Stock) and 3,000,000 shares authorized of Non Voting Convertible Preferred Stock, par value $1.00 . As of November 16,2018 Entest BioMedical, Inc. had 49,170,472 common shares outstanding, 728, 009 Series B Preferred shares outstanding , 667 Series AA preferred shares outstanding, 534 Series AAA preferred shares outstanding, and 1001533 shares of the Company’s Non Voting Convertible Preferred Stock outstanding.

~~The Company’s authorized~~(a) ~~capital~~Our ~~stock consists of 500,000,000 shares of~~ common stock ~~with~~is atraded ~~par~~on ~~value~~the ~~$0.0001,~~OTC ~~and~~Pink ~~5,000,000 shares~~Tier of ~~preferred~~OTC ~~stock~~Markets ~~with~~under athe ~~par~~symbol ~~value $0~~"ETNI”.~~0001~~ ~~per~~Below ~~share~~is ~~(of~~the ~~which~~range ~~100,000~~of ~~are~~high ~~designated as Series AA Preferred Stock, 4,400,000 are designated as Series B Preferred Stock~~ and ~~300,000~~low ~~are~~price ~~designated~~information asfor ~~Series~~our ~~AAA Preferred Stock) and 3,000,000 shares authorized of Non Voting Convertible Preferred Stock, par value $1.00 . As of November 22,2017 Entest BioMedical, Inc. had 49,171,072~~ common ~~shares~~ ~~outstanding,~~equity ~~728,~~for ~~009~~each ~~Series~~quarter Bwithin ~~Preferred~~the ~~shares~~last ~~outstanding~~two ,fiscal ~~667~~years ~~Series~~as AAreported ~~preferred~~by ~~shares~~OTC ~~outstanding, 533 Series AAA preferred shares outstanding, and 1001533 shares of the Company’s Non Voting Convertible Preferred Stock outstanding~~Markets.

(a) Our common stock is traded on the OTC Pink Tier of OTC Markets under the symbol "ENTB”. Below is the range of high and low bid information for our common equity for each quarter within the last two fiscal years. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions.5

September 1, 2015 to August 31, 2016	High		Low
September 1, 2017 to August 31, 2018	High		Low
First Quarter	$	0.~~043~~0182	$	0.010068
Second Quarter		0.~~0249~~0205		0.~~0061~~0068
Third Quarter		0.~~0145~~0405		0.~~0063~~0092
Fourth Quarter	$	0.~~0192~~054	$	0.~~0047~~011
September 1, 2016 to August 31, 2017		High		Low
First Quarter	$	0.0919	$	0.0038
Second Quarter		0.0559		0.02
Third Quarter		0.055		0.015
Fourth Quarter	$	0.0201	$	0.045

Holders

As of August 31, ~~2017~~2018 there were approximately ~~348~~40 holders of our Common Stock.

Dividends

No cash dividends were paid during the fiscal year ending August 31, ~~2017~~2018. We do not expect to declare cash dividends in the immediate future.

Recent Sales of Unregistered Securities

On September 8, 2017 the Company issued 2,500,000 Common Shares (“Shares”)in connection with a conversion of 25,000 Non Voting Convertible Preferred Shares.

OnThe ~~January~~Shares ~~27,~~were ~~2017~~issued ~~the~~pursuant ~~Company~~to ~~issued~~Section ~~100,000~~4(a) (2) of ~~its~~the ~~Common~~Securities ~~Shares~~Act of 1933, as amended (the “~~Shares~~Act”). No underwriters were retained to ~~Synergy~~serve ~~Business~~as ~~Consultants,~~placement ~~Inc~~agents for the sale. The shares were sold directly through our management. No commission or asother consideration ~~for~~was ~~services~~paid in connection with the sale of the shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

The Shares were issued pursuant to Section 4(a) (2) of the Securities Act of 1933, as amended. No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through our management. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares. A legend was placed on the certificate that evidences the Shares stating that the Shares have not been registered under the Act and setting forth or referring to the restrictions on transferability and sale of the Shares.

On February 7, 2017 the Company issued 1,000,000 of its Common Shares (“Shares”) in satisfaction of $10,000 of principal indebtedness.

On February 10, 2017 the Company issued 2,000,000 of its Common Shares (“Shares”)in satisfaction of $20,000 of principal indebtedness.

On March 10, 2017 the Company issued 100,000 of its Common Shares (“Shares”)as consideration for services.

On April 3, 2017 the Company issued 750,000 of its Common Shares (“Shares”) for consideration of $15,000

On May 30, 2017 the Company issued 100,000 of its Common Shares (“Shares”)to Synergy Business Consultants, Inc. as consideration for services.

On July 24, 2017 the Company issued 2,450,000 of its Common Shares (“Shares”) to consultants as consideration for services.

On September 8, 2017 the Company issued 2,500,000 Common Shares (“Shares”) in connection with a conversion of 25,000 Non Voting Convertible Preferred Shares.

Series B Preferred Shares

On March 10, 2017 the Company issued 500,000 of its Series B Preferred Shares(“Shares”) as additional consideration towards the purchase of investment securities.

On March 10, 2017 the Company issued 100,000 of its Series B Preferred Shares(“Shares”) as consideration for services

On March 31, 2017 the Company issued 100,000 of its Series B Preferred Shares (“Shares”) as consideration for services

Non Voting Convertible Preferred Shares

On May 30, 2017 the Company issued 840,681 of its Non Voting Convertible Preferred Shares (“Shares”) in satisfaction of $840,681 of principal indebtedness.

On May 30, 2017 the Company issued 83,000 of its Non Voting Convertible Preferred Shares (“Shares”) in satisfaction of $83,000 of expenses accrued but unpaid.

On July 24, 2017 the Company issued 102,852 of its Non Voting Convertible Preferred Shares (“Shares”) in satisfaction of $102,852 of expenses accrued but unpaid.

On September 8, 2017 25,000 of the Company’s Non Voting Convertible Preferred Shares were converted into 2,500,000 Common Shares (“Shares”)

Common Shares of Zander Therapeutics Inc.

On April 10, 2017 Zander issued 8,000 of its common shares (“Shares”) for consideration of $20,000.

On July 10, 2017 Zander issued 100,000 common shares (“Shares”)to the Chairman of Zander’s Business Advisory Board for consideration of $100,000.

On July 10, 2017 Zander issued 500,000 common shares (“Shares”) to the Chairman of Zander’s Business Advisory Board as consideration for services.

On October 30, Zander issued 900,000 of its common shares (“Shares”) for consideration of $900,000.

Preferred Shares of Zander Therapeutic, Inc.

On June 15, 2017 Zander issued 500,000 of its Series M Preferred Shares (“Shares”) to David Koos as consideration for services

On June 15, 2017 Zander issued 500,000 of its Series M Preferred Shares (“Shares”) to Harry Lander as consideration for services

On June 15, 2017 Zander issued 500,000 of its Series M Preferred Shares to Todd Caven (“Shares”) as consideration for services

On June 20, 2017 Zander issued 1,000,000 of its Series M Preferred Shares (“Shares”) for Services

On July 10, 2017 Zander issued 100,000 of its Series M Preferred Shares (“Shares”) for Services

On August 21, 2017 Zander issued 1,400,000 of its Series M Preferred Shares (“Shares”) for Services

On September 15, 2017 Zander issued 200 of its Series AA Preferred Shares (“Shares”) to David Koos, Zander’s Chief Executive Officer, for Services.

Item 6. Selected Financial Data

As we are a “smaller reporting company” as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

As of August 31, 2017, we had Cash in the amount of $86,559 and as of August 31, ~~2016~~2018 we had Cash in the amount of $~~859~~267.

The ~~increase~~decrease in ~~cash~~Cash of ~~9,979~~approximately 99.7% is primarily attributable to ~~sales~~the derecognition of ~~securities~~the ~~for~~assets ~~cash~~of ~~and~~Zander ~~additional~~Therapeutics, ~~borrowings offset by costs~~Inc. ~~incurred~~which inwas ~~the~~deconsolidated ~~operation~~from of the ~~business~~Company ofon ~~Entest~~June ~~and~~11, ~~Zander~~2018.

As of August 31, 2017 we had Accrued Interest Receivable of $908 and as of August 31 ~~2017~~2018 we had Accrued Interest Receivable of 0$1,040.

The increase in Accrued Interest Receivable isof ~~primarily~~approximately 14.2% is attributable to $132 of interest earned ~~but~~by ~~not~~the ~~yet~~Company ~~paid~~during the onquarter ~~funds~~ended ~~lent~~February to28, ~~Regen~~2018 ~~Biopharma, Inc.,~~resulting from a ~~company~~short ~~under~~term ~~common~~loan ~~control~~made ~~with~~by the Company, bythe principal on such loan paid during the ~~Company~~quarter ~~and~~ended ~~Zander~~February 28, 2018.

As of August 31, 2017 we had Prepaid Expenses of $58,652 and as of the end of the same period ended ~~2016~~2018 we had Prepaid Expenses of $8,000.

The ~~increase~~decrease in Prepaid Expenses of approximately ~~633~~86.3% is primarily attributable to $50,652 of fees prepaid to consultants during the fiscal year ended 2017.

~~As of August 31, 2017 we had Accrued Rent Receivable of 0 and as of the end of the same period of 2016 we had Accrued Rent Receivable of $15,000.~~6

~~The~~As ~~decrease~~of inAugust ~~Accrued~~31, ~~Rent~~2017 ~~Receivable~~we ishad ~~attributable~~Securities toAvailable ~~payment~~for Sale in ~~full~~the amount of ~~all~~$190,050 ~~rental~~and ~~charges~~as ~~incurred~~of byAugust ~~Regen Biopharma~~31, ~~Inc. due~~2018 towe ~~the~~had ~~Company.~~Securities Available ~~Regen~~for ~~Biopharma,~~Sale ~~Inc.~~in isthe ~~under~~amount ~~common~~of ~~control with the Company~~$0.

AsThe ofdecrease ~~August~~in ~~31, 2017 we had~~ Securities Available for Sale inis ~~the~~attributable ~~amount~~to ofthe ~~$190,050~~sale ~~and~~by asthe Company of ~~August 31~~3,500,000 ~~2016~~of wethe ~~had~~Series ~~Securities Available~~A ~~for~~Preferred ~~Sale~~shares of inRegen ~~the~~Biopharma, ~~amount~~Inc.to ofZander $0Therapeutics, Inc.

~~The~~David ~~increase~~R. inKoos, ~~Securities~~the ~~Available~~Chairman ~~for~~and ~~Sale~~Chief isExecutive ~~attributable~~Officer toof the ~~purchase by the~~ Company ~~of 3~~,~~500,000~~ ofserves in the ~~Series~~same Acapacity ~~Preferred shares~~at of Regen Biopharma, Inc. ~~from~~and anZander Therapeutics, ~~unaffiliated third party~~Inc.

As of August 31, 2017 we had ~~Accounts~~Notes Payable of $2813,~~446~~501 and as of August 31, ~~2016~~2018 we had ~~Accounts~~Notes Payable of $~~112~~19,~~162~~601.

The ~~decrease~~increase in ~~Accounts~~Notes Payable of approximately 7445.61% is ~~primarily~~ attributable to the incurrence of an additional $2,500 of principal indebtedness from the Company’s Chairman and incurrence of an additional $3,600 of principal indebtedness from an entity controlled by the Company’s Chairman.

~~(a)the~~As ~~derecognition~~of byAugust ~~the~~31, ~~Company~~2017 ~~during~~we ~~the~~had ~~quarter~~Accrued ~~ended~~Expenses ~~November 30, 2016~~ of $65269,~~092~~398 ofand ~~aged~~as ~~payables~~of ~~which~~August ~~are~~31, ~~effectively~~2018 ~~uncollectible by~~we ~~the~~had ~~creditors~~Accrued ~~due~~Expenses ~~to the expiration~~ of ~~the statute of limitations imposed upon such collection activity pursuant to relevant statute~~$181,904.

~~(b)~~The ~~the~~reduction ~~derecognition~~in byaccrued ~~the~~expenses ~~Company~~of approximately 32.4% is primarily attributable to payment during the ~~quarter~~year ended ~~May~~August 31, ~~2017~~ 2018 of $1188,~~605~~000 of ~~aged~~salary ~~payables~~accrued ~~which~~but ~~are~~unpaid ~~effectively~~to ~~uncollectible~~David R. Koos, the Company’s sole officer as well as derecognition of $818 of byaccrued interest during the ~~creditors~~year ~~due~~ended August 31 2018 attributable to the ~~expiration~~deconsolidation of ~~the~~Zander ~~statute~~Therapeutics, ofInc. ~~limitations~~offset by ~~imposed~~interest ~~upon~~accrued ~~such~~but ~~collection~~unpaid ~~activity~~due ~~pursuant~~on toNotes ~~relevant statute~~payable.

21As of August 31, 2018 we had Unearned Rental Income of $17,000 and as of August 31, 2017 we had Unearned Rental Income of $0.

AsThe ofincrease ~~August~~in ~~31,~~Unearned ~~2017~~Rental weIncome ~~had~~is ~~Notes~~attributable ~~Payable~~to ofrental ~~$13,501~~income ~~and~~prepaid asto ofthe ~~August~~Company 31by Regen Biopharma, ~~2016~~Inc. weRegen ~~had~~Biopharma, Inc. ~~Notes~~is ~~Payable~~under ofcommon ~~$455,601~~control with the Company.

~~The~~As ~~decrease~~of inAugust ~~Notes~~31, ~~Payable~~2018 we had a bank overdraft of ~~approximately~~$66 ~~97%~~and isas ~~primarily~~of ~~attributable~~August ~~to:~~31, 2017 we had a bank overdraft of $0.

The ~~settlement~~increase byin ~~the~~bank ~~Company~~overdraft ofis ~~$30,000~~attributable ofto ~~principal~~withdrawals ~~indebtedness~~of ~~through~~$66 ~~the~~in ~~issuance~~excess of ~~equity~~the ~~securities~~balance ~~during~~of ~~the~~a ~~nine~~bank ~~months ended~~account ~~May~~maintained ~~31,~~by ~~2017~~the Company.

~~The~~Revenues ~~settlement~~from ofcontinuing operations were $~~840~~0 for the year ended August 31,~~681~~ of2017 ~~principal~~and ~~indebtedness~~-0- ~~through~~for the ~~issuance~~year ofended ~~equity~~August ~~securities~~31, ~~during~~2018. ~~the~~Net ~~nine~~Losses ~~months~~from continuing operations were $664,792 for the year ended ~~May~~August 31, 2017 and $1,477,484 for the same period ended 2018.

~~Offset~~The byincrease ~~borrowings~~in Net Loss of approximately 122.2% is primarily attributable to Research and Development Fees incurred by Zander Therapeutics, Inc. during that period of the fiscal year during which Zander Therapeutics, Inc. was a consolidated subsidiary of the Company and ~~from~~recognition ~~third~~of ~~party~~the ~~lenders~~Company’s equity in the losses of Zander Therapeutics, Inc. during the period beginning June 11, 2018 and ending August 31, 2018. These losses were offset by gains on sale of investment securities and a one time gain of $10,034 recognized in connection with the deconsolidation of Zander Therapeutics, Inc.

~~As of August 31, 2017 we had Accrued Expenses of $269,398 and as of August 31, 2016 we had Accrued Expenses of $426,965.~~7

~~The~~As ~~decrease~~of inAugust ~~Accrued~~31, ~~Expenses~~2018 we had $267 cash on hand and current liabilities of ~~approximately~~$255,018 ~~36.9%~~such isliabilities ~~primarily~~consisting ~~attributable~~of Accounts Payable, Notes Payable, Amounts due to: Others and Accrued Expenses.

~~(a)~~We feel ~~Payment~~we ~~during~~will ~~the~~not ~~year~~be ~~ended~~able ~~August~~to ~~31,~~satisfy ~~2017~~our ofcash ~~$102,000~~requirements ofover ~~salary~~the ~~accrued~~next ~~but~~twelve ~~unpaid to David R~~months. ~~Koos,~~The ~~the~~ Company’s ~~sole~~seeks ~~officer. (b) Partial payment of $17,000~~ to ~~Regen~~acquire Biopharma, Inc. against $100,000 of expenses incurred as a result of that agreement entered into by and between Regen Biopharma, Inc. ( “Regen”) and Zander Therapeutics, Inc. ( “Zander”) whereby Regen granted to Zander an ~~exclusive~~operating company ~~worldwide~~seeking ~~right and license for~~ the ~~development~~perceived ~~and~~advantages ~~commercialization~~ of ~~certain~~being ~~intellectual property controlled by Regen for non-human veterinary therapeutic use for~~ a ~~term~~publicly ofheld ~~fifteen years~~corporation. ~~David~~No ~~Koos~~assurance ,can ~~CEO~~be ofgiven ~~the Company and Zander, serves as Chairman and Chief Executive Officer of Regen. (c) Settlement of $83,000 due to Regen Biopharma, Inc incurred as a result of~~ that ~~agreement~~such ~~entered~~an ~~into~~acquisition shall byoccur ~~and between Regen Biopharma~~or, ~~Inc.~~if (such ~~“Regen”) and Zander Therapeutics, Inc. ( “Zander”) whereby Regen granted to Zander~~ an ~~exclusive~~acquisition ~~worldwide~~were right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years. David Koos , CEO of the Company and Zander, serves as Chairman and Chief Executive Officer of Regen. (d) Settlement of $102,852 due to ~~Regen Biopharma~~occur, ~~Inc~~it ~~incurred~~would asoccur aon ~~result~~terms ~~of that agreement entered into by~~ and ~~between~~conditions ~~Regen~~beneficial ~~Biopharma, Inc. ( “Regen”) and Zander Therapeutics, Inc. ( “Zander”) whereby Regen granted~~ to ~~Zander an exclusive worldwide right and license for~~ the ~~development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years. David Koos , CEO of the~~ Company ~~and~~or ~~Zander, serves as Chairman and Chief Executive Officer of Regen~~its shareholders.

~~Offset~~As ~~by:~~of November 16, 2018 we are not party to any binding agreements which would commit Entest to any material capital expenditures.

$12,335 of accruals of interest payable during the quarter ended November 30, 2016.

$14,445 of accruals of interest payable during the quarter ended February 28, 2017.

$15,881 of accruals of interest payable during the quarter ended May 31, 2017.

$304 of accrued interest payable during the quarter ended August 31, 2017.

$957 of accrued tax payable incurred in connection with vesting of Restricted Stock Awards.

Material Changes in Results of Operations

Revenues from continuing operations were $0 for the year ended August 31, 2017 and -0- for the year ended August 31, 2016. Net Losses from continuing operations were $664,792 for the year ended August 31, 2017 and $506,690 for the same period ended 2016.

The increase in net losses from continuing operations of 31.2 % is primarily attributable to the recognition during the quarter ended February 28, 2017 of 107,700 of expense attributable to Issuance of Securities for less than Fair Value offset by the recognition during the quarter ended November 30, 2016 of $65,092 of income attributable to the derecognition of $65,092 of aged payables which are effectively uncollectible by the creditors due to the expiration of the statute of limitations imposed upon such collection activity pursuant to relevant statute and the recognition during the quarter ended May 31 , 2017 of $11,605 of income attributable to the derecognition by the Company during the quarter ended May 31, 2017 of $11,605 of aged payables which are effectively uncollectible by the creditors due to the expiration of the statute of limitations imposed upon such collection activity pursuant to relevant statute.

As of August 31, 2017 we had $86,559 cash on hand and current liabilities of $319,345 such liabilities consisting of Accounts Payable, Notes Payable, Amounts due to Others and Accrued Expenses.

We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

We currently plan to raise additional funds primarily by offering securities for cash.

There is no guarantee that we will be able to raise any capital through any type of offerings. We cannot assure that we will be successful in obtaining additional financing necessary to implement our business plan. We have not received any commitment or expression of interest from any financing source that has given us any assurance that we will obtain the amount of additional financing in the future that we currently anticipate. For these and other reasons, we are not able to assure that we will obtain any additional financing or, if we are successful, that we can obtain any such financing on terms that may be reasonable in light of our current circumstances.

As of November 22, 2017 we are not party to any binding agreements which would commit Entest to any material capital expenditures.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

As we are a smaller reporting company, as defined by Rule 229.10(f)(1), we are not required to provide the information required by this Item.

238

Item 8. Financial Statements and Supplementary Data

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

Entest ~~BioMedical~~Group, Inc. (FKA Entest Biomedical, Inc.)

WeOpinion ~~have~~on ~~audited~~ the ~~accompanying~~Financial balance sheet of Entest BioMedical, Inc. as of August 31, 2017 and August 31, 2016 and the related statements of operations, comprehensive income, stockholders’ equity, and cash flows for each of the years in the two-year period ended August 31, 2017. Entest BioMedical, Inc.’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.Statements

We ~~conducted~~have ~~our~~audited ~~audits~~the inaccompanying ~~accordance~~balance ~~with~~sheets ~~the standards~~ of ~~the~~Entest ~~Public~~Group, ~~Company~~Inc. ~~Accounting Oversight Board~~ (~~United~~the ~~States~~“Company”). ~~Those standards~~as ~~require~~of ~~that~~August we31, ~~plan~~2018 and ~~perform~~August 31, ~~the~~2017 ~~audit~~and ~~to obtain reasonable assurance about whether~~ the ~~financial~~related statements ~~are free~~ of ~~material~~operations, ~~misstatement.~~comprehensive ~~The~~income, ~~company~~stockholders’ ~~is not required to have~~equity, ~~nor~~and ~~were~~cash weflows ~~engaged~~for toeach ~~perform,~~of the anyears ~~audit~~in ofthe ~~its~~two-year ~~internal~~period ~~control over~~ended ~~financial~~August ~~reporting.~~31, ~~Our~~2018, ~~audit~~and ~~included~~the ~~consideration~~related ofnotes ~~internal~~and ~~control~~schedules ~~over~~(collectively ~~financial~~referred ~~reporting~~to as athe ~~basis for designing~~“financial ~~audit~~statements”). ~~procedures~~In ~~that~~our ~~are~~opinion, ~~appropriate in~~ the ~~circumstances,~~financial ~~but~~statements ~~not~~present ~~for~~fairly, ~~the~~in ~~purpose~~all ofmaterial ~~expressing~~respects, ~~an opinion on~~ the ~~effectiveness~~financial position of the ~~company’s~~Company ~~internal~~as ~~control~~of ~~over~~August ~~financial reporting. Accordingly~~31, we2018 ~~express~~and noAugust ~~such~~31, ~~opinion. An audit also includes examining~~2017, onand athe ~~test~~results ~~basis,~~of ~~evidence~~its ~~supporting~~operations ~~the amounts~~ and ~~disclosures~~its incash ~~the~~flows ~~financial~~for ~~statements,~~each ~~assessing~~of the ~~accounting~~ ~~principles~~years ~~used~~in ~~and~~the ~~significant~~two-year ~~estimates~~period ~~made~~ended byAugust ~~management~~31, as2018 ~~well~~in asconformity ~~evaluating~~with ~~the~~accounting ~~overall~~principles ~~financial~~generally ~~statement~~accepted ~~presentation. We~~in ~~believe~~the ~~that~~United ~~our~~States of ~~audits provide a reasonable basis for our opinion~~America.

InBasis our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Entest BioMedical, Inc. as of August 31, 2017 and August 31, 2016, and the results of its operations and its cash flows for ~~each of the years in the two-year period ended August 31, 2017 in conformity with accounting principles generally accepted in the United States of America.~~Opinion

~~The~~These ~~accompanying~~ financial statements ~~have~~are ~~been~~the ~~prepared~~responsibility ~~assuming~~of ~~that~~ the Company’s ~~will continue as a going concern~~management. AsOur ~~discussed in~~responsibility ~~Note~~is 4 to ~~the~~express ~~financial~~an ~~statements,~~opinion on the Company’s ~~has~~financial nostatements ~~revenues,~~based ~~has~~on ~~negative~~our ~~working~~audits. ~~capital~~We atare ~~August~~a ~~31,~~public ~~2017,~~accounting ~~has~~firm ~~incurred recurring~~registered ~~losses~~with ~~and~~the ~~recurring~~Public ~~negative~~Company Accounting ~~cash~~Oversight ~~flow~~Board ~~from~~(United ~~operating~~States) ~~activities,~~(“PCAOB”) and ~~has~~are anrequired ~~accumulated~~to ~~deficit~~be ~~which~~independent ~~raises~~with ~~substantial doubt~~respect ~~about its ability~~ to ~~continue~~the asCompany in aaccordance ~~going~~with ~~concern~~the U.S. ~~Management’s~~federal ~~plans~~securities ~~concerning~~laws ~~these~~and ~~matters~~the ~~are~~applicable ~~also~~rules ~~described~~and ~~in Note~~regulations 4.of ~~The~~the ~~financial~~Securities ~~statements~~and doExchange ~~not~~Commission and ~~include any adjustments that might result from~~ the ~~outcome of this uncertainty~~PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 4 to the financial statements, the Company has no revenues, has negative working capital at August 31, 2018, has incurred recurring losses and recurring negative cash flow from operating activities, and has an accumulated deficit which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 4. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ AMC Auditing

AMC Auditing We have served as the Company’s auditor since 2012

Las Vegas, Nevada

November 2719, ~~2017~~2018

249

Item 8. Financial Statements and Supplementary Data

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Balance Sheet


	As of August 31, 2018		August 31, 2017
ASSETS
Current Assets
Cash	267		86,559
Accrued Interest Receivable	1,040		908
Current Portion of Prepaid Expenses	8,000		58,652
Accrued Rent Receivable	0		0
Total Current Assets	9,307		146,119

OTHER ASSETS
Available for Sale Securities	0		190,050
Long Term Portion Prepaid Expenses	0		0
TOTAL ASSETS	9,307		336,169

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts Payable	28,447		28,446
Notes Payable	19,601		13,501
Due to Other	8,000		8,000
Unearned Rental Income	17,000		0
Bank Overdraft	66		0
Accrued Expenses	181,904		269,398
Total Current Liabilities	255,018		319,345
TOTAL LIABILITIES	255,018		319,345

STOCKHOLDERS' EQUITY
Common Stock, authorized 500,000,000 shares as of August 31, 2017 and August 31, 2018; issued and outstanding 46,670,472(par value $0.0001) as of August 31, 2017 and 49,170,472 as of August 31, 2018	4,911		4,661
Preferred Stock ,par value $0.0001 5,000,000 shares authorized, Series AA Preferred Stock, 100,000 shares authorized, 667 shares, par value $0.0001, issued and outstanding at August 31, 2017 and as of August 31, 2018	0		0
Series B Preferred 4,400,000 shares authorized, 728,009 ( par value $0.0001) issued and outstanding as of August 31, 2018 and 728,009 issued and outstanding as of August 31, 2017	73		73
Series AAA Preferred, 300,000 shares authorized, $0.0001 par value 534 shares outstanding as of August 31, 2018 and as of August 31, 2017
NonVoting Convertible Preferred ($1 par value) 3,000,000 shares authorized as of August 31, 2018 and August 31, 2017 respectively, 1,001,533 and 1,026,533 issued and outstanding as of August 31, 2018 and August 31, 2017, respectively	1,001,533		1,026,533
Additional Paid in Capital	8,729,236		7,191,000
Contributed Capital	274,662		274,662
Accumulated Deficit	(10,256,126	)	(8,721,498	)
Accumulated Other Comprehensive Income	0		185,050
Total Stockholders' Equity Entest Biomedical, Inc.	(245,711	)	(39,519	)
Non Controlling Interest Zander Therapeutics Inc.	0		56,343
Stockholders Equity	(245,711	)	16,824
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	9,307		336,169

The accompanying Notes are an integral part of these Financial Statements

ENTEST BIOMEDICAL, INC.
Consolidated Balance Sheet
	As of			As of
	August 31, 2017			August 31, 2016
ASSETS
Current Assets
Cash		86,559			859
Accrued Interest Receivable		908			—
Current Portion of Prepaid Expenses		58,652			8,000
Accrued Rent Receivable		0			15,000
Total Current Assets		146,119			23,859
OTHER ASSETS
Available for Sale Securities		190,050			—
TOTAL ASSETS		336,169			23,859
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts Payable		28,446			112,162
Notes Payable		13,501			455,601
Due to Other		8,000			8,000
Accrued Expenses		269,398			426,965
Total Current Liabilities		319,345			1,002,728
TOTAL LIABILITIES		319,345			1,002,728
STOCKHOLDERS' EQUITY
Common Stock, authorized 500,000,000 shares as of August 31, 2017 and August 31, 2016; issued and outstanding 46,670,472 (par value $0.0001) as of August 31, 2017 and 40,170,472 as of August 31, 2016		4,661			4,011
Preferred Stock ,par value $0.0001 5,000,000 shares authorized,
Series AA Preferred Stock, 100,000 shares authorized, 667 shares, par value $0.0001, issued and outstanding at August 31, 2017 and as of August 31, 2016		0			0
Series B Preferred 4,400,000 shares authorized, 28009 ( par value $0.0001) issued and outstanding as of August 31, 2016 and 728,009 issued and outstanding as of August 31, 2017		73			3
Series AAA Preferred, 300,000 shares authorized, $0.0001 par value 533 shares outstanding as of August 31, 2016 and as of August 31, 2017		0			0
NonVoting Convertible Preferred ($1 par value) 200,000 shares and 3,000,000 shares authorized as of August 31, 2016 and August 31, 2017 respectively, 0 and 1,026,533 issued and outstanding as of August 31, 2016 and August 31, 2017, respectively		1,026,533			0
Additional Paid in Capital		7,191,000			6,148,054
Contributed Capital		274,662			274,162
Accumulated Deficit		(8,721,498	)		(7,405,099	)
Accumulated Other Comprehensive Income		185,050			—
Total Stockholders' Equity Entest Biomedical, Inc.		(39,519	)		(978,869	)
Non Controlling Interest Zander Therapeutics Inc.		56,343
Stockholders Equity		16,824			(978,869	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY		336,169			23,859
The accompanying Notes are an integral part of these Financial Statements

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Operations


	Year Ended		Year Ended
	August 31, 2018		August 31 2017
TOTAL REVENUE	0		0
COSTS AND EXPENSES
Research and Development	949,584		124,770
Rent Costs	37,032		37,482
General and Administrative	224,263		225,804
Consultant's Expenses	310,020		263,823
Total Costs and Expenses	1,520,899		651,879

OPERATING LOSS	(1,520,899	)	(651,879	)

OTHER INCOME AND EXPENSE
Rental income	66,000		60,000
Interest Income	132		1,056
Gain on Write Off of Accounts Payable			76,697
Loss on Issuance of Stock Below Fair Value			(107,700	)
Gain on Deconsolidation of Zander	10,034
Equity in Losses of Zander	(61,428	)
Gain on Sale of Securities	30,000
Interest Expense	(1,323	)	(42,966	)
TOTAL OTHER INCOME AND EXPENSE	43,415		(12,913	)

LOSS BEFORE INCOME TAXES	(1,477,484	)	(664,792	)
Income Taxes	0		0

NET LOSS
NET LOSS from continuing	(1,477,484	)	(664,792	)
Operations
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.			105,374
NET LOSS available to common shareholders	(1,477,484	)	(559,418	)

BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS	(0.030	)	(0.013	)
WEIGHTED AVERAGE NUMBER COMMON SHARES OUTSTANDING	48987813		42551431

The accompanying Notes are an integral part of these Financial Statements

ENTEST BIOMEDICAL, INC.
Consolidated Statement of Operations
	12 Months Ended
	August 31, 2017			August 31, 2016
TOTAL REVENUE		0			0
COSTS AND EXPENSES
Research and Development		124,770			192,500
Rent Costs		37,482			41,667
General and Administrative		225,804			230,495
Consultant's Expenses		263,823			74,125
Total Costs and Expenses		651,879			538,787
OPERATING LOSS		(651,879	)		(538,787	)
OTHER INCOME AND EXPENSE
Rental income		60,000			60,000
Interest Income		1,056			—
Gain on Write Off of Accounts Payable		76,697			—
Loss on issuance of stock below fair value		(107,700	)		—
Interest Expense		(42,966	)		(27,903	)
Impairment of Property and equipment
TOTAL OTHER INCOME AND EXPENSE		(12,913	)		32,097
LOSS BEFORE INCOME TAXES		(664,792	)		(506,690	)
Income Taxes		—			—
NET LOSS
NET LOSS from continuing Operations		(664,792	)		(506,690	)
Less: (Net Income) Loss attributable to non controlling interest in Zander Therapeutics, Inc.		105,374			—
NET LOSS available to common shareholders		(559,418	)		(506,690	)
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS		(0.013	)		(0.013	)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		42,551,431			39,578,691
The accompanying Notes are an integral part of these Financial Statements

ENTEST GROUP, INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Comprehensive Income


		Year Ended August 31,			Year Ended August 31,
		2018			2017
Net Income (Loss)	$	(1477484	)	$	(664,792	)
Add:
Unrealized Gains on Securities		0			277,100
Less:
Unrealized Losses on Securities		0			(92,050	)
Comprehensive Income attributable to Non Controlling Interest		0			0
Total Other Comprehensive Income (Loss)		0			185,050
Comprehensive Income	$	(1477484	)	$	(479,742	)

The accompanying Notes are an integral part of these Financial Statements

ENTEST BIOMEDICAL, INC.
Consolidated Statement of Comprehensive Income
	Year Ended August 31,
	2017			2016
Net Income (Loss)	$	(664,792	)	$	(506,690	)
Add:
Unrealized Gains on Securities		277,100			0
Less:
Unrealized Losses on Securities		(92,050	)		0
Comprehensive Income attributable to Non Controlling Interest		0			0
Total Other Comprehensive Income (Loss)		185,050			0
Comprehensive Income	$	(479,742	)	$	(506,690	)
The accompanying Notes are an integral part of these Financial Statements

	Common				Series AA Preferred				Series AAA Preferred				Series B Preferred				Non Voting Convertible Preferred
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares			Amount			Additional Paid-in Capital			Contributed Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit during the Development Stage			Non Controlling interest In Subsidiary			Total
Balance August 31, 2016		40,170,472		4,011		667		0		533		0		28,009		3		0			0			6,148,054			274,162		0			(7,405,099	)		0			(978,869	)
Common Shares issued to Consultant January 27, 2017		100000		10																				4490														4,500
Common Shares issued for debt February 7, 2017		1000000		100																				9900														10,000
Common Shares issued for debt February 10, 2017		2,000,000		200																				19,800														20,000
Common Shares issued to Consultant March 10, 2017		100000		10																				4810														4,820
Series B Preferred shares issued to consultant March 10, 2017														500000		50																						50
Series B Preferred shares issued to consultant March 10, 2017														100000		10																						10
Series B Preferred shares issued to consultant March 31, 2017														100000		10																						10
Common Stock Issued for Cash April 3, 2017		750000		75																				14,925														15,000
Common Stock of Subsidiary sold for Cash April 10, 2017																								20,000														20,000
Common Shares issued to Consultant May 30, 2017		100000		10																				3,390														3,400
Shares issued for Accrued Expenses May 30, 2017																		83000			83000																	83,000
Shares issued for Debt May 30, 2017																		840681			840681																	840,681
Beneficial Conversion Features recognized May 30, 2017																								576,804														576,804
Amortization of Beneficial Conversion Feature May 30, 2017																																(576,804	)					(576,804	)
Preferred Shares of Subsidiary issued to consultants June 20, 2017																								100														100
Preferred Shares of Subsidiary issued to employees June 15, 2017																								150														150
Common Shares of Subsidiary issued for Cash July 10, 2017																								100,000														100,000
Common Shares of Subsidiary issued to Consultant 7/10/2017																								50														50
Preferred Shares of Subsidiary Issued to Consultants July 10, 2017																								10														10
Common Shares issued to Consultants July 24, 2017		2450000		245																				97,510														97,755
Shares issued for Accrued Expenses July 24, 2017																		102852			102852																	102,852
Beneficial Conversion Features recognized July 24, 2017																								74,801														74,801
Amortization of Beneficial Conversion Feature July 24, 2017																																(74,801	)					(74,801	)
Preferred Shares of Subsidiary Issued to Consultants August 21, 2017																								140														140
Restricted Stock Expense Recognized During the Year Ended August 31, 2017																								64,709														64,709
Accumulated Other Comprehensive Income Recognized During the Year Ended
August 31, 2017																													185050									185,050
Loss on Issuance below Fair Value																								107,700														107,700
Net Loss for the Year Ended August 31, 2017																																(664,792	)					(664,792	)
Non Controlling Interest in Subsidiary																								(56,343	)										56343			0
Increase in Contributed Capital Year Ended 8/31/2017																											500											500
Balance August 31, 2017		46,670,472		4,661		667		0		533		0		728,009		73		1,026,533			1,026,533			7,191,000			274,662		185050			(8,721,498	)		56343			16,824
Common Shares issued for NonVoting Convertible Preferred Shares September 8, 2017		2,500,000		250														(25,000	)		(25,000	)		24,750														0
Common Shares of Subsidiary issued for Cash October 30, 2017																								900,000														900,000
Common Shares of Subsidiary issued for Cash February 5, 2018																								200,000														200,000
Common Shares of Subsidiary issued for Cash February 27, 2018																								300,000														300,000
Declaration of property Dividend May 5, 2018																																(57,143	)					(57,143	)
Payment of Property Dividend June 11, 2018																								57,143														57,143
Elimination of Noncontrolling Interest upon deconsolidation June 11, 2018																								56,343											(56,343	)		0
Sale of Securities of Securities Available for Sale																													(185,050	)								(185,050	)
Net Loss For Year Ended August 31, 2018																																(1,477,484	)					(1,477,484	)
Balalnce August 31, 2018		49,170,472		4,911		667		0		533		0		728,009		73		1,001,533			1,001,533			8,729,236			274,662		0			(10,256,126	)		0			(245,711	)

The accompanying Notes are an integral part of these Financial Statements

ENTEST BIOMEDICAL, INC.
Consolidated Statement of Stockholders' Equity
For the Years Ended August 31, 2016 and August 31, 2017
	Common				Series AA Preferred				Series AAA Preferred				Series B Preferred				Non Voting Convertible Preferred
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital			Contributed Capital		Accumulated Other Comprehensive Income (Loss)		Accumulated Deficit during the Development Stage			Non Controlling Interest In Subsidiary		Total
Balance August 31, 2015		32,170,472		3,211		667		0		533		0		28,009		3		0		0		5,833,654			274,162				(6,898,409	)				(787,379	)
Common Shares issued for expenses September 28, 2015		8,000,000		800																		191,200												192,000
Restricted Stock Expense Recognized																						123,200												123,200
Net Loss Year Ended August 31 2016																													(506,690	)				(506,690	)
Balance August 31, 2016		40,170,472		4,011		667		0		533		0		28,009		3		0		0		6,148,054			274,162		—		(7,405,099	)		—		(978,869	)
Common Shares issued to Consultant January 27, 2017		100,000		10																		4,490												4,500
Common Shares issued for debt February 7, 2017		1,000,000		100																		9,900												10,000
Common Shares issued for debt February 10, 2017		2,000,000		200																		19,800												20,000
Common Shares issued to Consultant March 10, 2017		100,000		10																		4,810												4,820
Series B Preferred shares issued to consultant March 10, 2017														500,000		50																		50
Series B Preferred shares issued to consultant March 10, 2017														100,000		10																		10
Series B Preferred shares issued to consultant March 31, 2017														100,000		10																		10
Common Stock Issued for Cash April 3, 2017		750,000		75																		14,925												15,000
Common Stock of Subsidiary sold for Cash April 10, 2017																						20,000												20,000
Common Shares issued to Consultant May 30, 2017		100,000		10																		3,390												3,400
Shares issued for Accrued Expenses May 30, 2017																		83,000		83,000														83,000
Shares issued for Debt May 30, 2017																		840,681		840,681														840,681
Benificial Conversion Feautures recognized May 30, 2017																						576,804												576,804
Amortization of Beneficial Conversion Feauture May 30, 2017																													(576,804	)				(576,804	)
Preferred Shares of Subsidiary issued to consultants June 20, 2017																						100												100
Preferred Shares of Subsidiary issued to employees June 15, 2017																						150												150
Common Shares of Subsidiary issued for Cash July 10, 2017																						100,000												100,000
Common Shares of Subsidiary issued to Consultant 7/10/2017																						50												50
Preferred Shares of Subsidiary Issued to Consultants July 10, 2017																						10												10
Common Shares issued to Consultants July 24, 2017		2,450,000		245																		97,510												97,755
Shares issued for Accrued Expenses July 24, 2017																		102,852		102,852														102,852
Benificial Conversion Feautures recognized July 24, 2017																						74,801												74,801
Amortization of Beneficial Conversion Feauture July 24, 2017																													(74,801	)				(74,801	)
Preferred Shares of Subsidiary Issued to Consultants August 21, 2017																						140												140
Restricted Stock Expense Recognized During the Year Ended August 31, 2017																						64,709												64,709
Accumulated Other Comprehensive Income Recognized During the Year Ended
31-Aug-17																											185,050							185,050
Loss on Issuance below Fair Value																						107,700												107,700
Net Loss for the Year Ended August 31, 2017																													(664,792	)				(664,792	)
Non Controlling Interest in Subsidiary																						(56,343	)									56,343		0
Increase in Contributed Capital Year Ended 8/31/2017																									500									500
Balance August 31, 2017		46,670,472		4,661		667		0		533		0		728,009		73		1,026,533		1,026,533		7,191,000			274,662		185,050		(8,721,498	)		56,343		16,824
The accompanying Notes are an integral part of these Financial Statements

ENTEST GROUP,INC.
(Formerly called ENTEST BIOMEDICAL, INC.)
Consolidated Statement of Cash Flow
(unaudited)


	Year Ended		Year Ended
	August 31, 2018		August 31, 2017
OPERATING ACTIVITIES
Net (loss)	(1,477,484	)	(664,792	)
Adjustments to reconcile net loss to net cash used by operating activities:
Increase(Decrease) in stock of subsidiary issued to employees			150
Increase(Decrease) in stock of subsidiary issued to consultants			300
Increase (Decrease) in Additional paid in Capital	0		64,709
Increase ( Decrease) in Issuance of Stock below Faie Value	0		107,700
increase (Decrease) in Preferred Stock issued for expenses	0		185,852
Increase (Decrease) in Preferred Stock issued to Consultants			70
(Increase) Decrease in Gain attributable to Deconsolidation	(10,034	)
(Increase) Decrease Cash Lost in Deconsolidation	(332,638	)
Equity in Losses of Zander	61,428
Increase (Decrease) Common Stock issued to Consultants			110,475
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses	(117,388	)	(50,652	)
Increase(Decrease) in Unearned Rent	17,000
Increase (Decrease) in Accounts Payable	454,494		(83,716	)
(Increase) Decrease in Accrued Rental Income Receivable	0		15,000
Increase (Decrease) in Accrued Expenses	(85,347	)	(157,566	)
(Increase )Decrease in Accrued Interest Receivable	(132	)	(909	)
(Increase) Decrease in Notes Receivable
Net Cash Provided (Used) in Operating Activities	(1,490,101	)	(473,380	)

Net Cash Provided ( Used) in Investing Activities:
Securities Purchased for Cash			(5,000	)
Gain on Sale of Securities received prior to deconsolidation	(2,357	)
Net Cash Provided ( Used) in Investing Activities:	(2,357	)	(5,000	)
FINANCING ACTIVITIES
Net Cash Provided (Used) in Financing Activities:
Common Stock issued for cash			15,000
Common Stock of Subsidiary issued for cash	1,400,000		120,000
Increase (Decrease) in Notes Payable	6,100		428,580
Increase(Decrease) Bank Overdraft	66
Increase (Decrease) in Contributed Capital			500
Net Cash Provided by Financing Activities	1,406,166		564,080

Net (Decrease) Increase in Cash	(86,292	)	85,700

Cash at Beginning of Period	86,559		859

Cash at End of Period	267		86,559

Supplemental Disclosure of Non CashInvesting and Financing Activities:
Common Stock Issued for Debt			30,000
Preferred Stock issued for Debt			840,681

The accompanying Notes are an integral part of these Financial Statements

ENTEST BIOMEDICAL, INC.
Consolidated Statement of Cash Flows
	Twelve Months Ended
	August 31, 2017			August 31, 2016
OPERATING ACTIVITIES
Net (loss)		(664,792	)		(506,690	)
Adjustments to reconcile net loss to net cash used in operating activities:
Increase (Decrease) in Common Stock issued to consultants		110,475			—
Increase (Decrease) in Stock of Subsidiary issued to consultants		300			—
Increase (Decrease) in Stock of Subsidiary issued to employees		150			—
Increase (Decrease) in Preferred Stock issued to consultants		70			—
Increase (Decrease) in Additional paid in Capital		64,709			123,200
Increase (Decrease) in Common Stock issued for expenses					192,000
Increase (Decrease) in Preferred Stock issued for expenses		185,852			—
Increase in issuance of stock below fair value		107,700			—
Changes in Operating Assets and Liabilities
(Increase) Decrease in Prepaid Expenses		(50,652	)		—
Increase (Decrease) in Accounts Payable		(83,716	)		5,737
(Increase) Decrease in Accrued Rental Income Receivable		15,000			(5,000	)
(Increase) Decrease in Accrued Interest Receivable		(909	)		—
(Increase) Decrease in Notes Receivable		0			—
Increase (Decrease) in Accrued Expenses		(157,566	)		147,391
Net Cash Provided (Used) in Operating Activities		(473,380	)		(43,362	)
INVESTING ACTIVITIES
Securities Purchased for Cash		(5,000	)		—
Net cash Provided by (Used in) Investing Activities		(5,000	)		—
FINANCING ACTIVITIES
Common Stock Issued for cash		15,000			—
Common Stock of Subsidiary issued for cash		120,000			—
Increase (Decrease) in Notes Payable		428,580			42,062
Increase (Decrease) in Contributed Capital		500			—
Net Cash Provided by Financing Activities		564,080			42,062
Net (Decrease) Increase in Cash		85,700			(1,300	)
Cash at Beginning of Period		859			2,159
Cash at End of Period		86,559			859
Supplemental Disclosure of Noncash investing and financing activities:
Common Stock issued for Debt		30,000
Preferred Stock issued for Debt		840,681
Cash Paid During the Year for Interest					512
The accompanying Notes are an integral part of these Financial Statements

29The Entest Group,Inc.

~~Entest~~(formerly ~~BioMedical~~known as Entest Biomedical, Inc.)

Notes to Consolidated Financial Statements

As of August 31, ~~2017~~2018

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Entest Biomedical, Inc ( The “Company”) was incorporated in the State of Nevada on September 24, 2008 as JB Clothing Corporation. Until July 10, 2009, the Company’s principal business objective was the offering of active/leisure fashion design clothing.

On July 10, 2009 the Company abandoned its efforts in the field of active/leisure fashion design clothing when it acquired 100% of the share capital of Entest BioMedical, Inc., a California corporation, (“Entest CA”).

On June 18, 2015 the Company formed Zander Therapeutics, Inc. (“Zander”) , a Nevada corporation. ~~Zander~~As isof aAugust ~~63.45%~~31, ~~owned~~2018 ~~subsidiary~~Entest ofowns ~~the~~Zander ~~Company~~34.82% as of ~~August 31, 2017~~Zander.

~~The~~On ~~Company~~February ~~intends~~12, to2018 ~~engage primarily in~~ the ~~development~~Company ofchanged ~~veterinary~~its ~~medical~~name ~~applications which we intend~~ to ~~license~~The ~~from~~Entest ~~other entities~~Group, ~~as well as develop internally~~Inc.

As of August 31, 2018 the Company is a “Shell Company” as such term is defined in Rule 12(b)(2) promulgated under the Securities and Exchange Act of 1934 . This Rule defines as Shell Company as a company that has:

(1) No or nominal operations; and

(2) Either:

(i) No or nominal assets;

(ii) Assets consisting solely of cash and cash equivalents; or

(iii) Assets consisting of any amount of cash and cash equivalents and nominal other assets.

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted an August 31 fiscal year-end. The Company recognizes revenue from services and product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of Entest CA, the Company’s wholly owned subsidiary. ~~and~~These ~~Zander;~~financial statement also include the ~~Company’s~~ ~~majority~~accounts ~~owned~~of ~~subsidiary~~Zander up to June 10, 2018. Significant inter-company transactions have been eliminated.

C. USE OF ESTIMATES

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

D. CASH EQUIVALENTS

The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

E. PROPERTY AND EQUIPMENT

As of August 31, ~~2017~~2018 Property and Equipment consists of $0

F. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level 1: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company’s financial instruments as of August 31, ~~2017~~2018 consisted of $13 19,~~501~~601 of Notes Payable and $8,000 due to TheraCyte, Inc.. The fair value of all of the Company’s financial instruments as of August 31, ~~2017~~2018 were valued according to the Level 3 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company.

The Company has determined that there are no Level 1 or Level 2 inputs for determining the fair value of the Company’s financial instruments. Fair value was determined by the Company utilizing its own assumptions and estimation. There were no transfers between levels for the period presented.

G. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “ Income Taxes. ” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting for Uncertainty in Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of August 31, ~~2017~~2018 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

H. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All convertible debt has an anti-dilutive effect on the EPS, therefore Diluted earnings per share are the same as basic earnings per share.

NOTE 3. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

The following accounting standards updates were recently issued and have not yet been adopted by the Company. These standards are currently under review to determine their impact on the Company’s consolidated financial position, results of operations, or cash flows.

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

NOTE 4. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $810,~~721~~256,~~498~~126 during the period from August 22, 2008 (inception) through August 31, ~~2017~~2018. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Management ~~plans~~intends to ~~raise~~seek ~~additional~~business ~~funds~~opportunities ~~primarily by offering securities for cash. Management has yet~~ to ~~decide~~review ~~what~~and ~~type~~analyze of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings. During the quarter ended May 31, 2017 Entest Biomedical, Inc. raised $15,000 through the sale for ~~cash~~purposes of ~~equity~~effecting ~~securities.~~a ~~During the quarter ended May 31~~merger, ~~2017~~acquisition ~~Zander~~or ~~Therapeutics,~~other ~~Inc. raised $20,000 through~~business ~~the~~combination ~~sale~~with ~~for~~an ~~cash~~operating ofcompany ~~equity securities~~business. ~~During the quarter ended August 31, 2017 Zander Therapeutics, Inc. raised $100,000 through the sale for cash of equity securities.~~

NOTE 5. NOTES PAYABLE

As of August 31, ~~2017~~2018

Notes Payable:

David Koos ( See Note 6)	$	100
David Koos (See Note 6)	$	2,600
Dunhill Ross Partners, Inc.	$	850
Blackbriar Partners (See Note 6)	$	811,~~000~~600
Regen Biopharma, Inc (See Note 6)	$	4,551
Total	$	1319,~~501~~601

$1,000 lent to the Company by Blackbriar Partners is due and payable February 17, 2018 and bears simple interest at a rate of 10% per annum

$7,000 lent to the Company by Blackbriar Partners is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum.

$3,000 lent to the Company by Blackbriar Partners is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum.

$600 lent to the Company by Blackbriar Partners is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.

Blackbriar Partners is controlled by David R. Koos , the Company’s sole officer and director.

As of August 31, 2017 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $100 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% per annum.18

~~Amounts~~As ~~due to Regen Biopharma Inc. as~~ of August 31, ~~2017~~2018 ~~are due and payable at~~ the ~~demand~~Company ofremains ~~the~~indebted ~~holder~~to ~~and bear simple interest at a rate of 10% per annum.~~ David R. Koos , the Company’s sole officer, ~~serves as Chairman~~ and ~~Chief~~director, ~~Executive~~in ~~officer~~the ~~of Regen~~principal ~~Biopharma,~~amount ~~Inc.~~of ~~Harry Lander~~$2,600 ~~President~~due and ~~Chief~~payable ~~Scientific~~in ~~Officer~~whole ofor ~~Regen~~in ~~Biopharma~~part ~~Inc.~~at ~~serves~~the asdemand ~~President~~of ~~and~~David ~~Chief~~Koos ~~Scientific Officer~~and ofbearing ~~Zander~~simple ~~Therapeutics,~~interest ~~Inc.~~at ~~The~~a ~~Chief~~rate ~~Financial Officer~~ of ~~Regen Biopharma, Inc.is Todd Caven who also serves as Chief~~15% ~~Financial~~per ~~Officer of Zander Therapeutics, Inc~~ annum.

33Amounts due to Regen Biopharma Inc. as of August 31, 2018 are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

NOTE 6. RELATED PARTY TRANSACTIONS

As of August 31, ~~2017~~2018 the Company remains indebted to David R. Koos , the Company’s sole officer and director, in the principal amount of $~~100~~2,600 due and payable in whole or in part at the demand of David Koos and bearing simple interest at a rate of 15% ~~per~~ per annum.

As of August 31, ~~2017~~2018 the Company remains indebted to Blackbriar Partners in the principal amount of $811,~~000~~600 of which $1,000 is due and payable February 17, 2018 and bears simple interest at a rate of 10%per annum and of which $7,000 is due and payable February 28, 2018 and bears simple interest at a rate of 10% per annum , of which$3,000 is due and payable May 4, 2019 and bears simple interest at a rate of 10% per annum and of which $600 is due and payable August 20, 2019 and bears simple interest at a rate of 10% per annum.

AsBlackbriar ofPartners ~~August~~is ~~31,~~controlled ~~2017~~by the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $4,551 due and payable in whole or in part at the demand of the holder and bearing simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, ~~serves as Chairman~~ and ~~Chief Executive officer of Regen Biopharma, Inc~~director. Harry Lander, President and Chief Scientific Officer of Regen Biopharma Inc. serves as President and Chief Scientific Officer of Zander Therapeutics, Inc. The Chief Financial Officer of Regen Biopharma, Inc.is Todd Caven who also serves as Chief Financial Officer of Zander Therapeutics, Inc .

As of August 31, 2018 the Company remains indebted to Regen Biopharma, Inc. in the principal amount of $4,551 due and payable in whole or in part at the demand of the holder and bearing simple interest at a rate of 10% per annum. David R. Koos , the Company’s sole officer, serves as Chairman and Chief Executive officer of Regen Biopharma, Inc.

On October 1, 2014 Regen Biopharma Inc. entered into an agreement to sublease approximately 2,320 square feet of office space from the Company. Entest Biomedical Inc. is under common control with Regen Biopharma, Inc. as the Chairman and CEO of the Company also serves as the Chairman and CEO of Regen Biopharma, Inc. The sublease is on a month to month basis and rent payable to the Company by Regen Biopharma Inc is equal to the rent payable to the lessor by the Company and is to be paid in at such time specified in accordance with the original lease agreement between the Company and the lessor. On January 20, 2015 the sublease was amended retroactive to January 1, 2015 as follows:

The rent payable to Entest BioMedical, Inc. by the subtenant is equal to Five Thousand Dollars per month ($5,000) and is to be paid in at such time specified in accordance with the original lease agreement between the Entest BioMedical, Inc. (“Entest”) and the lessor. All charges for utilities connected with premises which are to be paid under the master lease shall be paid by Regen Biopharma, Inc. for the term of this sublease to the extent that such charges exceed the difference between the rent payable to the lessor by Entest under the master lease and the rent payable to Entest by Regen Biopharma, Inc.

On June 23, 2015 Regen Biopharma, Inc. ( “Regen”) entered into an agreement (“Agreement”) with Zander whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen (“ License IP”) for non-human veterinary therapeutic use for a term of fifteen years.19

~~Pursuant~~On toFebruary ~~the~~28, ~~Agreement~~2016, ~~Zander~~the ~~shall~~Company ~~pay~~purchased tofrom ~~Regen~~a ~~one-time,~~third ~~non-refundable~~party 3,500,000 ~~upfront~~shares ~~payment~~of the Series A Preferred stock of ~~one~~Regen ~~hundred~~Biopharma, Inc ~~thousand~~for USconsideration ~~dollars~~consisting (of $~~100~~5,000~~) as~~ acash ~~license~~and ~~initiation~~500,000 ~~fee~~shares ~~which~~of ~~must~~the beCompany’s ~~paid~~Series ~~within~~B 90Preferred ~~days~~Stock. ofOn ~~June~~July 233, 2018 ~~2015~~the ~~and~~Company ansold ~~annual~~the ~~non-refundable~~aforementioned ~~payment~~3,500,000 ofshares ~~one~~to ~~hundred thousand~~Zander USfor ~~dollars~~consideration (consisting of $~~100~~35,000). onDavid ~~July~~R. ~~15th~~Koos, ~~2016~~who serves as Chairman and ~~each~~Chief ~~subsequent~~Executive ~~anniversary~~Officer of ~~the~~Zander ~~effective~~also ~~date~~serves as Chairman and Chief Executive Officer of ~~the~~Entest. ~~Agreement~~Zander is under common control with Entest.

~~The~~On ~~abovementioned~~July ~~payments may be made~~3, at2018 Zander’s ~~discretion,~~entered ininto ~~cash~~a orsublease ~~newly~~agreement ~~issued~~with ~~common~~Entest ~~stock~~whereby of Zander orwould insublet ~~common stock~~office ofspace ~~Entest~~located ~~BioMedical~~at ~~Inc.~~4700 ~~valued~~Spring Street, asSuite of304, ~~the~~La ~~lowest~~Mesa, ~~closing~~California ~~price~~91942 onfrom ~~the~~Entest ~~principal~~on ~~exchange~~a ~~upon~~month ~~which~~to ~~said~~month ~~common~~basis ~~stock~~for ~~trades publicly~~$6,000 ~~within~~per ~~the~~month 14beginning ~~trading~~July ~~days~~5, ~~prior to issuance~~2018.

~~Pursuant~~David toR. ~~the Agreement~~Koos, ~~Zander~~who ~~shall~~serves ~~pay~~as toChairman ~~Regen~~and ~~royalties~~Chief ~~equal~~Executive toOfficer ~~four percent (4%)~~ of ~~the~~Zander ~~Net~~also ~~Sales~~serves , as ~~such~~Chairman ~~term~~and isChief ~~defined~~Executive ~~in the~~Officer ~~Agreement,~~ of ~~any~~Entest. Zander ~~Licensed Products, as such term~~ is ~~defined~~under incommon ~~the~~control ~~Agreement,~~with ~~in a Quarter~~Entest.

Pursuant to the Agreement, Zander will pay Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees ( excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment pursuant to the terms and conditions of the Agreement).

Zander is obligated pay to Regen minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

The Agreement may be terminated by Regen:

If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to Regen with regard to that License IP.

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to Regen with regard to that License IP is terminated.

The Agreement may be terminated by either party in the event of a material breach by the other party.

On September 28, 2015 the Company issued 8,000,000 of its common shares to Regen in satisfaction of the license initiation fee.

During the quarter ended November 30, 2016 the Company paid $17,000 to Regen as a partial payment of the July 15th, 2016 liability.

On May 30, 2017 the “Company issued 83,000 shares of its Non Voting Convertible Preferred Stock (“ Shares”) to Regen in satisfaction of $83,000 of the July 15th, 2016 liability.

On July 24, 2017 the Company issued 102,852 of its Non Voting Convertible Preferred Stock (“ Shares”) to Regen in satisfaction of $102,852 of liabilities incurred pursuant to the Agreement.

On February 28, 2016, the Company purchased from a third party 3,500,000 shares of the Series A Preferred stock of Regen Biopharma, Inc for consideration consisting of $5,000 cash and 500,000 shares of the Company’s Series B Preferred Stock.

During the quarter ended August 31, 2017, David R. Koos , the Company’s Chairman and Chief Executive Officer, satisfies a $500 Account Payable to an unrelated party on behalf of the Company. The Company is under no obligation to repay this amount to David R. Koos.

NOTE 7. INCOME TAXES

As of August 31, 2017
As of August 31, 2018
Deferred tax assets:
Net operating tax carry forwards	$	2,~~969~~156,~~949~~652
Other		-0-
Gross deferred tax assets		2,~~969~~156,~~949~~652
Valuation allowance		(2,~~969~~156,~~949~~652	)
Net deferred tax assets	$	-0-

35As of August 31, 2018 the Company has a Deferred Tax Asset of $2,156,652 completely attributable to net operating loss carry forwards of approximately $ 10,269,773(which expire 20 years from the date the loss was incurred) consisting of:

As(a) of$ ~~August 31~~13,647 ~~2017 the Company has a Deferred Tax Asset~~ of ~~$2,969,949~~Net ~~completely~~Operating ~~attributable~~Loss ~~to net operating loss~~ carry forwards of ~~approximately~~acquired ~~$8,735,145(which~~in ~~expire~~the 20reverse ~~years~~acquisition ~~from~~of ~~the~~Entest ~~date~~BioMedical, ~~the~~Inc., ~~loss~~a ~~was~~California ~~incurred) consisting of:~~corporation, and

(ab) $13 10,~~647~~256,126 of Net Operating Loss carry forwards ~~acquired~~attributable into ~~the reverse acquisition of~~ Entest BioMedical, Inc.~~, a California corporation, and~~

~~(b)~~Realization of ~~$8,721,498~~deferred oftax ~~Net~~assets ~~Operating~~is ~~Loss~~dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards ~~attributable~~are expected to be available to reduce taxable income. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved in 2009 has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to $ -0-.

~~Realization~~Income ~~of deferred~~ tax ~~assets~~ is ~~dependent~~calculated ~~upon~~at ~~sufficient future taxable income during~~ the ~~period~~21% ~~that~~Federal ~~deductible~~Corporate ~~temporary differences and carry forwards are expected to be available to reduce taxable income~~Rate. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. In addition, the reverse acquisition in which Entest BioMedical, Inc. was involved in 2009 has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has recorded a valuation allowance reducing all deferred tax assets to $-0-.

Income tax is calculated at the 34% Federal Corporate Rate.

NOTE 8. ACQUISITION OF ENTEST CA

On July 10, 2009 the Company acquired 100% of Entest CA, a California corporation and wholly owned subsidiary of the Company, from BMSN for consideration consisting of (a) the issuance to BMSN of 10,000,000 newly issued common shares of Entest and (b) the return by Mr. Rick Plote of 10,000,000 shares of Entest’s common stock previously issued to him by Entest for cancellation.

NOTE 9. ACQUISITION OF THE ASSETS OF PET POINTERS, INC.

On January 4, 2011 Entest CA acquired from Pet Pointers, Inc., a California corporation doing business as McDonald Animal Hospital (“Seller”), and Dr. Gregory McDonald DVM (“McDonald”) all the goodwill from McDonald and assets of Seller except cash and accounts receivables used in connection with the operation of a veterinary medical clinic located at 225 S. Milpas Street, Santa Barbara, CA 93103 (the "Business").

Consideration for the acquisition consisted of:

I. $70,000 in cash

II. $210,000 of the Company’s common shares valued at the closing price per share as of January 4, 2011

III. Payment of no more than $78,000 to a creditor of the Seller to be paid in monthly installments of $1,500 per month

IV. Payment of no more than $25,000 to additional creditors of the Seller to be paid in monthly installments of $825 per month

V. Payment of $50,000 to McDonald on the first business day of the fourth month following the closing of the acquisition (“Closing”).

NOTE 10. DISPOSITION OF THE ASSETS OF PET POINTERS, INC.

On November 28, 2012 the “Company executed an agreement (“Agreement”) with Gregory McDonald ("McDonald"), Pet Pointers, Inc. ("Pet Pointer") whereby Mc Donald and Pet Pointer would acquire from the Company all assets (with the exception of cash and accounts receivable) utilized by the Company in the operation of the McDonald Animal Hospital, a full service veterinary clinic owned and operated by the Company and located in Santa Barbara, California (“McDonald Asset Sale”).

On October 10, 2012 a Complaint (“Complaint”) was filed in the Superior Court of the State of California against the Company and David Koos by McDonald, a former employee of the Company, alleging breach of contract and breach of the covenant of good faith and dealing in connection with the assumption of lease obligations by the Company in connection with the acquisition of the assets of Pet Pointers, Inc breach of contract and breach of the covenant of good faith and dealing in connection with an employment agreement enters into with McDonald inc connection with the Acquisition, breach of contract in connection with the Acquisition purchase agreement, breach of the covenant of good faith and dealing in connection with the Acquisition purchase agreement, implied indemnity in connection to amounts owed by McDonald to Anthony and Judi Marinelli, the Internal Revenue Service, and the California Franchise Tax Board, intentional misrepresentation, negligent misrepresentation , failure to pay wages and violations of Sections 2802, 203, and 2806 of the California Labor Code. The Complaint sought judgment for nominal damages, actual damages, compensatory damages, lost wages, compensation, expenses wage benefits and penalties pursuant to California Labor Code Sections 203 et al, 2802 and 2806, indemnification, accrued interest, punitive damages, costs of suit and attorney’s fees.

As consideration to the Company for the assets acquired, McDonald and Pet Pointers provided to the Company a General release whereby McDonald and Pet Pointer waive, release and discharge the Company and their respective assignees, officers, directors, shareholders, boards, owners, employees, attorneys, agents, trustors, trustees, beneficiaries, heirs, successors, and representatives from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses including:

(1) All claims relating to the Complaint.

(2) Those owed by McDonald to Anthony and Judi Marinelli which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(3) Those amounts owed by McDonald to the Internal Revenue Service which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

(4) Those amounts owed by McDonald to the California Franchise Tax Board which the Company became obligated to pay on McDonald’s behalf pursuant to the asset purchase agreement entered into between the Company and Gregory McDonald and Pet Pointers, Inc on January 4, 2011.

Assets disposed of pursuant to the Agreement include approximately $4,840 of Property Plant and Equipment net of accumulated depreciation as well as all inventory held at the McDonald Animal Hospital.

Assets disposed of pursuant to the Agreement also include

(i) Essentially all intellectual property, including computer software, utilized in connection with the operation of the McDonald Animal Hospital

(ii) All telephone numbers, fax numbers, service marks, trademarks, trade names, fictitious business names, websites, business email addresses, vendor lists, promotional materials, vendor records and any and all business records including, but not limited to, such items stored in computer memories, microfiche, paper record or by any other means relevant to the operation of the McDonald Animal Hospital.

(iii) All customer lists, customer contacts, and any and all customer records that are related to the McDonald Animal Hospital.

As a result of the agreement, the Company recorded a non-cash pre-tax charge for the impairment of goodwill recorded in connection with the acquisition of the McDonald Animal Hospital of approximately $405,000 for the quarter ended November 30, 2012.

Pursuant to the Agreement, the Company is obligated to make payment of $13,000 within five days of the Closing of the Agreement as such term is defined in the Agreement.

Pursuant to the Agreement, the Company agrees to waive, release and discharge McDonald and Pet Pointer from all known and unknown claims, demands, causes of action, attorney's fees, costs, or expenses.

37NOTE 11. DECONSOLIDATION OF ZANDER THERAPEUTICS, INC.

~~NOTE~~On 11May 5, 2018, The Company declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., ~~COMMITMENTS~~par ~~AND~~value ~~CONTINGENCIES~~$0.0001, currently owned by Entest Group, Inc. to:

(a) Holders of record of the outstanding common shares of the Company as of the record date, which is May 30, 2018.

(b) Holders of record of the shares of any outstanding series of the preferred shares of the Company as of the record date, which is May 30, 2018.

Shareholders of the Company shall receive one (1) common share of Zander Therapeutics, Inc. for each 17 common and/or preferred shares of the Company held as of the record date. The distribution of the 3,000,000 common shares of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 ("Distribution Date").

As a result of the payment of the abovementioned property dividend, the Company’s percentage of ownership of Zander fell below 50% resulting in the deconsolidation of Zander as of the Distribution Date. As of the Distribution Date all assets and liabilities attributable to Zander were derecognized by the Company. The Company recognized a $10,034gain as a result of the deconsolidation. The Property dividend may be deemed to have occurred with a related party as the recipients were shareholders of Entest, including the Chairman and Chief Executive Officer of Entest and Regen Biopharma, Inc. which is a company under common control with Entest.

The Company’s remaining share of Zander , which consists of 5,000,000 shares of Zander’s Series M Preferred Stock (“Zander M Stock”) is accounted for under the Equity Method as of the Distribution Date. The Zander M Stock is carried a Fair Value and the carrying value is increased by the Company’s proportionate share of earnings of Zander and decreased by cash dividends paid by Zander as well as the Company’s proportionate share of losses of Zander up to the carrying value . As of August 31, 2018 the carrying value of the Zander M Stock has been decreased by the Company’s proportionate share of the losses of Zander and is 0. As of August 31, 2018 Entest beneficially owns 34.82% of the share equity of Zander.

5 million shares of Zander Series M Preferred Stock received by the Company on June 15, 2017 in consideration of services rendered has been valued by the Company as of the deconsolidation date utilizing the following inputs:

Fair Value of Intellectual Property	1,030
prepaid Expenses	168,000
Accounts Payable	454,493
Due from Entest	7,357
Accrued Expenses	2,148
Enterprise Value	633,028
Less: Total Debt	(463,998	)
Enterprise Value available to Shareholders	169,030
Per Share	0.012286

The Chairman and Chief Executive Officer of the Company and Zander is David R. Koos. Zander may be considered a related party of the Company.

SUMMARY INFORMATION FOR ZANDER THERAPEUTICS ,INC. FOR THE FISCAL YEAR ENDED AUGUST 31, 2018

Revenue	0
Operating Loss	(2,801,376	)
Net Loss	(2,780,288	)
Portion of Net Loss attributable to Entest	(968,188	)

NOTE 12. COMMITMENTS AND CONTINGENCIES

Filing Compare · ENTEST GROUP, INC.